IDEA

March 25, 2024 03:38 AM GMT

Asia Quantitative Strategy | Asia Pacific

Biweekly Perspectives: Rising Signs Of Market Late-Cycle


The unwinding of Momentum trades in APxJ/EM and outperformance of Low Quality stocks flag signs of market transition to late-cycle. Our model forecasts higher market volatility ahead and a potential Momentum reversal in Japan in April. QUANTWISE

Key Takeaways

- Alpha efficacy of mid-cycle factors have been fading out in Asia, via Momentum trade unwinding, crowded short covering on low Quality names.
- Such unwinding was the most significant in APxJ over the last four weeks; we see a potential unwinding of Japan Momentum trades in April as likely.
- Concurrently, style rotation and price actions in Asia/EM are mostly responding to flows and risk sentiment, but not macro factors, e.g. UST yields.
- These are the signs of transition from mid-cycle to late-cycle factor landscape.
 Our quant model suggests taking Low Volatility strategy for now.

Market dynamics & signs of Late-cycle: Our quant model has been classifying Asia/ EM equities in a mid-cycle phase since March 2023, and recommended picking stocks with Price Momentum, Balance Sheet Quality, and Consensus Revisions Leadership. However, their alpha efficacy has been fading sequentially since February. Per our last Biweekly, we discussed that the elevated factor volatility might lead the factor landscape to transition to late-cycle. In March MTD, we note that the sensitivity between Value/Growth rotation vs. UST 10Y yield (and DXY) has also been deteriorating. Such trading pattern rhymes with what we saw during historical late-cycles, and adds to our conviction to prefer Low Volatility style.

Exhibit 1: Historical Performance In A Market Cycle - Asia/EM



Source: FactSet, Bloomberg, MSCI, Morgan Stanley Research. Note: data coverage is from January 1995 to March 22, 2024, covering 10 market capitulation scenarios of MSCI EM - Sep 10, 1998, Oct 3, 2001, Oct 10, 2002, May 17, 2004, Jun 13, 2006, Mar 2, 2009, Oct 4, 2011, Jan 21, 2016, Oct 29, 2018, Mar 23, 2020. Past performance is no guarantee of future results.

MORGAN STANLEY ASIA LIMITED+

Gilbert Wong, CFA

Quantitative Strategist

Gilbert.Wong@morganstanley.com +852 2848-7102

Jason Ng, CFA

Quantitative Strategist

Jason.Dl.Ng@morganstanley.com +852 2848-8845

MORGAN STANLEY ASIA (SINGAPORE) PTE.+

Jonathan F Garner

Equity Strategist

Jonathan.Garner@morganstanley.com +65 6834-8172

Daniel K Blake

Equity Strategist

Daniel.Blake@morganstanley.com +65 6834-6597

MORGAN STANLEY ASIA LIMITED+

Crystal Ng

Equity Strategist

Crystal.Ng@morganstanley.com +852 2239-1468

Morgan Stanley does and seeks to do business with companies covered in Morgan Stanley Research. As a result, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of Morgan Stanley Research. Investors should consider Morgan Stanley Research as only a single factor in making their investment decision

For analyst certification and other important disclosures, refer to the Disclosure Section, located at the end of this report.

+= Analysts employed by non-U.S. affiliates are not registered with FINRA, may not be associated persons of the member and may not be subject to FINRA restrictions on communications with a subject company, public appearances and trading securities held by a research analyst account.

Market Dynamics and Style Implications

-4.0%

-6.0%

Value

Growth

Latest Style Performance Overview in Asia/EM

Momentum trades unwinding continued in APxJ/EM & The rising signs of Late-cycle

Factor Dynamics: We note that the majority of market mid-cycle factors, e.g. Quality, Price Momentum, Consensus Revisions, were all fading out in alpha efficacy in March MTD (Exhibit 2). Meanwhile, the sensitivity of Value/Growth rotation against macro factors, e.g. UST bond yields, DXY, were deteriorating. These phenomenon were often seen in the historical late-cycle phase, in which investor sentiment and flows were the dominant drivers behind the market price actions.

Meanwhile, the higher factor volatility and correlations across factors also lowered the diversification effect within equity investors' portfolios. Total volatility of the equity market is on the rise, and if it evolves further, hedge funds' deleveraging might accelerate, triggering further unwinding of Momentum trades (Exhibit 3).

3.0% 2.3% 2.0% 2.0% 1.1% 0.5% 0.5% 0.5% 0.5% 1.1% -0.6% -1.6

Earnings

Small Cap

-5.6%

Momentum

Low Beta

Exhibit 2: L/S factor return of major styles and factors - APxJ/EM equities

Source: FactSet, Morgan Stanley Research; data as of March 22, 2024; Past performance is no guarantee of future results.

Quality




Exhibit 3: Price Momentum factor performance in current cycle vs. history

Source: FactSet, Bloomberg, MSCI, Morgan Stanley Research. Note: data coverage is from January 1995 to March 22, 2024, covering 10 market capitulation scenarios of MSCI EM - Sep 10, 1998, Oct 3, 2001, Oct 10, 2002, May 17, 2004, Jun 13, 2006, Mar 2, 2009, Oct 4, 2011, Jan 21, 2016, Oct 29, 2018, Mar 23, 2020. Past performance is no guarantee of future results.


In Japan, Momentum trade is slowing down: March is a typical month when Japan's Price Momentum factor outperforms, and the same trading pattern repeated again this year.

But if we compare the MTD vs. YTD performance, we note there are some changes in the market micro-structure level, implying that the Momentum trade in Japan might see a reversal shortly.

The most significant one is the fade out of the momentum of Large-cap stocks in Japan in March MTD. Per what we discussed in the last Biweekly Perspectives, the top crowding risk in Japan was in Large-Cap stocks, particularly Banks and Automobiles, as of February month-end. However, the relative performance of Large-cap vs. Small-mid cap turned out to be muted in March. (Exhibit 4)


Secondly, we believe the seasonal tailwind of Japan Momentum trade may turn to be a headwind in April, as investors tend to cover shorts after dividend ex-dates. Our model recognizes a high consistency that Japan market price actions tend to trade on a reversal basis, in which stocks with high short interest outperformed. (Exhibit 5)

Exhibit 4: L/S factor return of major styles and factors – Japan equities



Source: FactSet, Morgan Stanley Research; data as of March 22, 2024; Past performance is no guarantee of future results.

Exhibit 5: Historical short interest flows & factor performance in Japan before and after March/September month-end




Source: IHS Markit, FactSet, Morgan Stanley Research; data coverage: 1996 to 2023.

Macro and Market Dynamics That Matter

The charts and paragraphs below illustrate our latest views on market dynamics and style recommendations.

i) Our model continues to highlight on-going risk of Momentum trades unwinding. Such unwinding has been dominated by "crowded short covering", which drove Chinese Growth/Tech stocks to outperform in Asia/EM since February. If history is any guide, the next phase of unwinding will likely be about the "crowded long selling", and Japan Momentum stocks, in particular those in Semis, Automobiles, and Financials, might face a short term headwind in April.

Exhibit 6: Momentum factor return in China, Japan, and US



Source: Bloomberg, Morgan Stanley Research; data as of March 22, 2024.

ii) Growth outperformed Value despite a higher UST 10Y Yield (Exhibit 8): Bond futures markets have been pricing out Fed rate cut expectations YTD. US treasury bond yields trended higher in the last two weeks. However, Bond volatility (MOVE Index) trended lower, and JPY also depreciated against USD. In our quant model, these macro dynamics are taken as offsetting factors of tighter financial conditions.

With support from short covering flows among Growth/Tech stocks, outperformance of Growth over Value has continued into March MTD, rounding up an in-line relative return of these two major styles in Asia/EM.

110 2.5 1.5 1.0 0.5 Jan-17 Jul-17 Jan-18 Jul-18 Jan-19 Jul-19 Jan-20 Jul-20 Jan-21 Jul-21 Jan-22 Jul-22 Jan-23 Jul-23 Jan-24 Jul-24 Jan-25 MSCI Japan Value/Growth UST 10Y Yield - RHS -- - MS f/c (new)


Exhibit 7: US treasury 10Y bond yields vs. Value/Growth relative performance in Asia/EM

Source: Bloomberg, MSCI, Morgan Stanley Research; data coverage from January 1, 2017 to March 8, 2024. Past performance is no guarantee of future results.

iii) Risk-off sentiment remains in Asia/EM: According to Morgan Stanley's Asia Risk Sentiment Indicator (Exhibit 8), overall risk allocation among global asset owners continues to prefer low-risk assets as money market funds dominate fund inflows, and their appetite for EM equity funds remained lackluster. Per our flows tracking via EPFR data, net fund flows to EM equity have been on and off on a weekly basis YTD. We believe the strong DXY remains the key macro driver behind that.

Comparing the risk sentiment in Asia vs. that in the US, we note a major decoupling with growing signs of greedy sentiment in US equity and global HY markets (Exhibit 8). In our view, this could potentially lead to Momentum reversal in Asia, stemming from US equity market.





Source: FactSet, Bloomberg, EPFR, MSCI, Morgan Stanley Research. Note: Buy/Sell signals are generated if average weekly readings of the risk sentiment indicator in the last four weeks were below the 15th percentile or above the 85th percentile. The above red/green lines are tracking the forward 6M returns since the signal appeared. MSARSI methodology and its other details can be referred to in insight #1 in the QuantASIA launch report. Past performance is no guarantee of future results.


4 -Morgan Stanley Global Risk Demand Index (GRDI) 3 2 0 -1 -2 -3 -4 -5 Mar-19 Mar-20 Mar-21 Mar-22 Mar-23 Mar-24

Exhibit 9: Morgan Stanley Global Risk Demand Index - as of March 22, 2024

Source: Bloomberg, Morgan Stanley Research


iv) Factor performance indicates that the market is in transition from mid-cycle to late-cycle phase: We note that various market mid-cycle factors have been losing their alpha efficacy from February onward. Many fundamentally solid companies underperformed in Asia/EM. i.e. stocks with high Quality balance sheets and consensus revisions leadership turned to underperform. Such a reversal of this long-lasting trading pattern is a meaningful sign that the market is no longer in a mid-cycle phase. From a quant perspective, we prefer Low Volatility strategy, and we suggest investors put risk management as the #1 thing to focus on in market late-cycle phase.

Exhibit 10: Factor performance of "MS Balance Sheet Quality Composite" before and after market troughs



Source: FactSet, Bloomberg, MSCI, Morgan Stanley Research. Note: data coverage is from January 1995 to March 22, 2024, covering 10 market capitulation scenarios of MSCI EM - Sep 10, 1998, Oct 3, 2001, Oct 10, 2002, May 17, 2004, Jun 13, 2006, Mar 2, 2009, Oct 4, 2011, Jan 21, 2016, Oct 29, 2018, Mar 23, 2020. Past performance is no guarantee of future results.

Exhibit 11: Factor performance of "Consensus Earnings Revision" before and after market troughs



Source: FactSet, Bloomberg, MSCI, Morgan Stanley Research. Note: data coverage is from January 1995 to March 22, 2024, covering 10 market capitulation scenarios of MSCI EM - Sep 10, 1998, Oct 3, 2001, Oct 10, 2002, May 17, 2004, Jun 13, 2006, Mar 2, 2009, Oct 4, 2011, Jan 21, 2016, Oct 29, 2018, Mar 23, 2020. Past performance is no guarantee of future results.

Short Interest Update – March 22, 2024

- 1. Utilization ratio of security lending market increased in the region MTD, in which Asia ex China led the new short position adding.
- 2. In China, short interest remained largely unchanged MTD, with cyclical sectors, like Energy and Materials seeing higher short interest, while non-cyclical sectors, e.g. Utilities, Info Tech, recorded short covering.
- 3. In Japan, outstanding short interest increased MTD as seasonality trade on Japan dividend ex-date repeated.

Exhibit 12: Changes in Utilization Ratio of Market/Sector (as of March 22, 2024 vs. prior month average); positive changes mean adding shorts, negative values mean covering shorts

MSCI Classification	А	хJ	China		Ja	pan
Utilization Ratio	Latest	Change vs. Last Month	Latest	Change vs. Last Month	Latest	Change vs. Last Month
Energy	6.3	2.3	5.6	2.7	13.3	9.0
Materials	22.2	-0.9	17.0	1.9	11.5	5.8
Industrials	22.4	0.3	13.5	0.6	11.3	7.6
Consumer Discretionary	8.6	0.6	5.5	-0.3	9.2	0.7
Consumer Staples	12.9	-1.6	14.3	-0.9	7.0	3.7
Health Care	26.2	-10.6	19.1	0.8	7.2	4.3
Financials	10.9	4.8	4.4	-0.4	16.4	13.6
Information Technology	14.0	4.2	9.7	-2.0	7.0	-3.6
Communication Services	5.4	1.3	2.3	0.5	10.9	5.0
Utilities	11.5	0.5	7.5	-2.0	9.9	-22.7
Real Estate	10.4	-1.1	14.7	-0.9	9.3	6.0
In Aggregate	12.7	2.0	6.6	0.1	10.2	5.3

Source: IHS Markit, FactSet, Morgan Stanley Research

Note: The Utilization Ratio highlights the balance between demand and supply of stock loans. A stock might appear to have low levels of short interest only due to its lack of availability for shorting purposes. The Utilization Ratio measures the percentage of supply being covered by demand, and is calculated as short interest/actively available amount of stock loan supply. The active element refers to IHS Markit adjustments for small or inactive inventory.

Exhibit 13: Top 10 Increases and Decreases in Short Interest Value Among AxJ Companies – As of March 22, 2024

AxJ	Company Name	GICS Sector	Short Interest Value (US\$m)			Days to Cover
6488-TW	GlobalWafers Co., Ltd.	Information Technology	413	299	70.9	26.10
ZTO-US	ZTO Express (Cayman), Inc. Sponsored ADR Class A	Industrials	320	259	15.0	5.67
2317-TW	Hon Hai Precision Industry Co., Ltd.	Information Technology	533	227	1.4	11.33
2603-TW	Evergreen Marine Corp. (Taiwan) Ltd.	Industrials	304	211	48.9	3.67
5-HK	HSBC Holdings Plc	Financials	425	210	51.3	2.71
2454-TW	MediaTek Inc	Information Technology	428	209	0.5	1.85
BIDU-US	Baidu Inc Sponsored ADR Class A	Communication Services	340	181	9.5	1.08
669-HK	Techtronic Industries Co., Ltd.	Industrials	291	165	3.1	8.07
HTHT-US	H World Group Limited Sponsored ADR	Consumer Discretionary	423	162	15.9	5.49
3231-TW	Wistron Corporation	Information Technology	493	151	48.1	2.32
2330-TW	Taiwan Semiconductor Manufacturing Co., Ltd.	Information Technology	365	(1,342)	0.5	0.63
NIO-US	NIO Inc. Sponsored ADR Class A	Consumer Discretionary	2,163	(382)	75.1	8.20
1876-HK	Budweiser Brewing Co. APAC Ltd.	Consumer Staples	74	(212)	25.8	2.18
005930-KR	Samsung Electronics Co., Ltd.	Information Technology	597	(199)	0.0	0.80
U14-SG	UOL Group Limited	Real Estate	8	(150)	1.9	0.33
BABA-US	Alibaba Group Holding Limited Sponsored ADR	Consumer Discretionary	917	(132)	10.8	0.68
005490-KR	POSCO Holdings Inc.	Materials	529	(121)	12.8	3.46
005935-KR	Samsung Electronics Co Ltd Pfd Non-Voting	Information Technology	58	(119)	100.0	1.01
17-HK	New World Development Co. Ltd.	Real Estate	125	(108)	65.3	6.16
3443-TW	Global Unichip Corp.	Information Technology	246	(105)	85.3	1.86

Source: FactSet, IHS Markit, Morgan Stanley Research. For important disclosures regarding companies that are the subject of this screen, please see the Morgan Stanley Research Disclosure Website at www.morganstanley.com/researchdisclosures.

Exhibit 14: Top 10 Increases and Decreases in Short Interest Value Among China Companies – as of March 22, 2024

China	Company Name	GICS Sector	Short Interest Value (US\$m)			Days to Cover
ZTO-US	ZTO Express (Cayman), Inc. Sponsored ADR Class A	Industrials	320	259	15.0	5.67
BIDU-US	Baidu Inc Sponsored ADR Class A	Communication Services	340	181	9.5	1.08
HTHT-US	H World Group Limited Sponsored ADR	Consumer Discretionary	423	162	15.9	5.49
9868-HK	XPeng, Inc. Class A	Consumer Discretionary	646	151	48.1	12.62
3690-HK	Meituan Class B	Consumer Discretionary	231	144	0.7	0.70
JD-US	JD.com, Inc. Sponsored ADR Class A	Consumer Discretionary	629	104	53.3	2.51
700-HK	Tencent Holdings Ltd.	Communication Services	247	98	0.3	0.42
YUMC-US	Yum China Holdings, Inc.	Consumer Discretionary	336	97	4.7	2.14
EH-US	EHang Holdings Ltd. Sponsored ADR Class A	Industrials	177	89	95.9	28.93
3968-HK	China Merchants Bank Co., Ltd. Class H	Financials	254	78	4.1	3.03
NIO-US	NIO Inc. Sponsored ADR Class A	Consumer Discretionary	2,163	(382)	75.1	8.20
BABA-US	Alibaba Group Holding Limited Sponsored ADR	Consumer Discretionary	917	(132)	10.8	0.68
354-HK	Chinasoft International Ltd.	Information Technology	61	(96)	12.7	3.85
NTES-US	Netease Inc Sponsored ADR	Communication Services	67	(95)	2.9	0.48
2359-HK	WuXi AppTec Co., Ltd. Class H	Health Care	145	(83)	23.4	2.22
9633-HK	Nongfu Spring Co., Ltd. Class H	Consumer Staples	312	(76)	15.4	21.68
6030-HK	CITIC Securities Co. Ltd. Class H	Financials	98	(74)	5.7	6.25
1833-HK	Ping An Healthcare and Technology Company Limited	Consumer Staples	56	(69)	65.0	6.03
853-HK	MicroPort Scientific Corp.	Health Care	32	(62)	56.1	2.29
257-HK	China Everbright Environment Group Limited	Industrials	33	(62)	46.0	2.25

Source: FactSet, IHS Markit, Morgan Stanley Research. For important disclosures regarding companies that are the subject of this screen, please see the Morgan Stanley Research Disclosure Website at www.morganstanley.com/researchdisclosures.

Exhibit 15: Top 10 Increases and Decreases in Short Interest Value Among Japan Companies – as of March 22, 2024

JP	Company Name	GICS Sector	Short Interest Value (JPYm)	Changes vs. Last Month	Utilization Ratio (%)	Days to Cover
7267-JP	Honda Motor Co., Ltd.	Consumer Discretionary	238,480	152,844	16.1	8.67
6920-JP	Lasertec Corp.	Information Technology	253,067	139,127	17.0	0.91
2914-JP	Japan Tobacco Inc.	Consumer Staples	214,975	132,350	7.1	10.40
7751-JP	Canon Inc.	Information Technology	274,584	111,654	7.4	16.16
4519-JP	Chugai Pharmaceutical Co., Ltd.	Health Care	193,793	110,416	2.7	13.86
1605-JP	Inpex Corporation	Energy	116,247	78,431	4.9	7.65
4324-JP	Dentsu Group Inc.	Communication Services	101,817	73,294	6.8	24.95
5108-JP	Bridgestone Corporation	Consumer Discretionary	147,730	71,490	2.1	10.71
6326-JP	Kubota Corporation	Industrials	157,959	68,453	4.0	18.89
6723-JP	Renesas Electronics Corporation	Information Technology	220,102	60,965	5.7	4.24
7203-JP	Toyota Motor Corp.	Consumer Discretionary	228,353	(230,475)	7.8	1.80
6758-JP	Sony Group Corporation	Consumer Discretionary	30,316	(168,813)	1.1	0.52
6861-JP	Keyence Corporation	Information Technology	21,184	(124,261)	0.7	0.55
6857-JP	Advantest Corp.	Information Technology	117,280	(111,440)	9.9	1.07
7974-JP	Nintendo Co., Ltd.	Communication Services	79,644	(109,688)	4.2	1.63
4568-JP	Daiichi Sankyo Company, Limited	Health Care	9,964	(67,815)	0.8	0.50
6501-JP	Hitachi,Ltd.	Industrials	102,710	(63,639)	2.6	3.92
8035-JP	Tokyo Electron Ltd.	Information Technology	159,859	(59,482)	3.3	1.15
8001-JP	Itochu Corporation	Industrials	531,535	(40,657)	30.7	22.14
4063-JP	Shin-Etsu Chemical Co Ltd	Materials	64,524	(39,248)	1.9	1.76

Source: FactSet, IHS Markit, Morgan Stanley Research. For important disclosures regarding companies that are the subject of this screen, please see the Morgan Stanley Research Disclosure Website at www.morganstanley.com/researchdisclosures.


Factor Monitor – Biweekly Update March 22, 2024

Methodology

Factor return calculation: To evaluate historical factor performance, we rank stocks as at month-end within defined universes, and form quintile portfolios based on the underlying factor values. We go long the top quintile and short the bottom quintile (i.e., long the top 20th percentile of stocks within the defined universe and short those in the bottom 20th percentile), rebalanced monthly. We then calculate the performance of the time series of this L/S market-neutral portfolio over various time horizons.

Composite formation: To calculate the composite factors, we first z-score the individual factor values at each monthly observation within the defined universe. Individual factor z-scores are then averaged into composite scores for each stock on an equal-weighted basis.

Exhibit 16: Morgan Stanley Factor Structure (Definitions can be found in Appendix – Factor Definitions)



Source: Morgan Stanley Research


Asia Pacific ex Japan – Factor Monitor

Exhibit 17: Asia Pacific ex Japan – Factor Performance Summary

As of:	3/22/2024	Asia Pacific ex Japan							
Category	Factor Description	Mar MTD	Feb	YTD					
Deep Value	Cheap P/B Cheap P/S Cheap P/E	1.4% 1.8% 0.8%	2.5% 1.1% 1.8%	3.9% 3.0% 2.6%					
Defensive Value Current Value Quality Value	High Total Yield Cheap Fwd P/E High FCF Yield	0.7% 2.5% 0.5%	-1.6% 3.2% -1.5%	-0.9% 5.8% -1.0%					
	Value Composite	1.0%	3.0%	4.1%					
Quality	Low Accruals High Earnings Stability High Profitability Low Leverage High Operating Efficiency	-1.0% 1.0% -1.3% 0.2% -0.3%	-0.2% -0.3% -0.2% 3.7% -1.2%	-1.2% 0.7% -1.5% 3]9% -1.5%					
	Quality Composite	-1.0%	-0.5%	-1.5%					
Growth	High Internal Growth High Dividend Growth High Earnings Growth High Long Term Growth f/c	-1.0% -0.5% -0.5% 2.5%	2.6% 0.4% 3.9% 2.5%	1.6% -0.1% 3.4% 5.0%					
	Growth Composite	-1.2%	1.6%	0.4%					
Sentiment	1M Loser 12M-1M Residual Return Earnings Revision Sales Revision	-1.1% 1.0% -0.1% 0.7%	4.2% 3.2% 1.9% 0.2%	3.1% 4.2% 1.8% 1.0%					
	Sentiment Composite	1.6%	4.9%	6.6%					
Technicals	12M Price Momentum Small Cap Low Trading Liquidity High Short Ratio High DTC Short High Short Utilization	-0.8% -1.8% -1.5% -1.4% 	-2.0% 1.0% -4.5% 5.5% 3.7% 3.9%	-2.9% 2.8% -6.0% 6.9% 4.6%					
	Low Volatility Low Beta	-0.8%		-7.9% -7.3%					

Source: FactSet, Morgan Stanley Research

Exhibit 18: Cumulative L/S Alpha since 2022 – Asia Pacific ex Japan



Source: FactSet, Morgan Stanley Research

Exhibit 19: Value Factors: Cumulative L/S Alpha since 2022 – Asia Pacific ex Japan



Exhibit 21: Quality Factors: Cumulative L/S Alpha since 2022 – Alpha Asia Pacific ex Japan




Source: FactSet, Morgan Stanley Research

Exhibit 23: Growth Factors: Cumulative L/S Alpha since 2022 – Asia Pacific ex Japan




Source: FactSet, Morgan Stanley Research

Exhibit 20: Value Factors: L/S Alpha Asia Pacific ex Japan



Source: FactSet, Morgan Stanley Research

Exhibit 22: Quality Factors: L/S Alpha Asia Pacific ex Japan



Source: FactSet, Morgan Stanley Research

Exhibit 24: Growth Factors: L/S Alpha Asia Pacific ex Japan




Exhibit 25: Sentiment Factors: Cumulative L/S Alpha since 2022 – Asia Pacific ex Japan




Exhibit 27: Other Factors: Cumulative L/S Alpha since 2022 – Asia Pacific ex Japan




Source: FactSet, Morgan Stanley Research

Exhibit 26: Sentiment Factors: L/S Alpha Asia Pacific ex Japan



Source: FactSet, Morgan Stanley Research

Exhibit 28: Other Factors: L/S Alpha Asia Pacific ex Japan



Source: FactSet, Morgan Stanley Research

Asia ex Japan – Factor Monitor

Exhibit 29: Asia ex Japan – Factor Performance Summary

As of:	3/22/2024	1	Asia ex Japaı	า
Category	Factor Description	Mar MTD	Feb	YTD
Deep Value	Cheap P/B Cheap P/S Cheap P/E	1.3% 1.8% 1.2%	2.7% 1.7% 1.6%	4.0% 3.5% 2.8%
Defensive Value	High Total Yield	1.0%	-0.6%	0.4%
Current Value	Cheap Fwd P/E	2.8%	3.4%	6.3%
Quality Value	High FCF Yield	0.4%	-1.7%	-1.4%
	Value Composite	1.3%	2.9%	4.3%
Quality	Low Accruals High Earnings Stability High Profitability	-0.9% 1.0% -1.4%	-0.2% 0.5% -0.5%	-1.1% 1.5% -1.8%
	Low Leverage High Operating Efficiency	1.1% -0.4%	3.3% -1.2%	4.5% -1.6%
	Quality Composite	-1.2%		
Growth	High Internal Growth High Dividend Growth High Earnings Growth High Long Term Growth f/c	-0.5% -0.6% -0.7% 2.9%	0.5% 3.6%	2.0% -0.1% 2.9% 2.8%
	Growth Composite	-1.3%	0.6%	-0.7%
Sentiment	1M Loser 12M-1M Residual Return Earnings Revision Sales Revision	-1.2% 1.0% 0.0% 0.7%	3.8% 3.5% 1.9% 0.5%	2.6% 4.5% 1.8% 1.3%
	Sentiment Composite	1.6%	5.2%	6.9%
Technicals	12M Price Momentum Small Cap Low Trading Liquidity High Short Ratio	-0.9% 18% -1.5% 1.2%	0.5% -4.4% 5.4%	2.3% -5.9% 6.7%
	High DTC Short High Short Utilization Low Volatility Low Beta	0.2% 0.6% -0.9% -2.5%	3.8% 4.3% -7.3% -5.3%	

Source: FactSet, Morgan Stanley Research

Exhibit 30: Cumulative L/S Alpha since 2021 – Asia ex Japan



Exhibit 31: Value Factors: Cumulative L/S Alpha since 2022 – Asia ex Japan



Exhibit 33: Quality Factors: Cumulative L/S Alpha since 2022 – Asia ex Japan




Source: FactSet, Morgan Stanley Research

Exhibit 35: Growth Factors: Cumulative L/S Alpha since 2022 – Asia ex Japan




Source: FactSet, Morgan Stanley Research

Exhibit 32: Value Factors: L/S Alpha Asia ex Japan




Source: FactSet, Morgan Stanley Research

Exhibit 34: Quality Factors: L/S Alpha Asia ex Japan



Source: FactSet, Morgan Stanley Research

Exhibit 36: Growth Factors: L/S Alpha Asia ex Japan



Source: FactSet, Morgan Stanley Research

Exhibit 37: Sentiment Factors: Cumulative L/S Alpha since 2022 – Asia ex Japan




Exhibit 39: Other Factors: Cumulative L/S Alpha since 2022 – Asia ex Japan




Source: FactSet, Morgan Stanley Research

Exhibit 38: Sentiment Factors: L/S Alpha Asia ex Japan



Source: FactSet, Morgan Stanley Research

Exhibit 40: Other Factors: L/S Alpha Asia ex Japan




Emerging Markets – Factor Monitor

Exhibit 41: Global EM – Factor Performance Summary

Deep Value		
Deep Value	YTD	
Current Value Cheap Fwd P/E 2.6% 1.9% 4.5 Quality Value High FCF Yield 1.2% 3.1% -1.5 Value Composite 0.8% 2.3% 3.1 Low Accruals -0.8% 0.4% -0.3 High Earnings Stability -0.2% 0.0% -0.2 Quality -1.8% -2.9 -1.8% -2.9 Low Leverage 0.5% 2.2% 2.2 2.2 High Operating Efficiency -1.0% -0.6% -1.6 Quality Composite -1.6% -1.3% -3.0 High Internal Growth -1.5% 1.8% 0.3 High Dividend Growth -0.2% 1.2% 1.0 High Earnings Growth -1.3% 4.6% 3.2 High Long Term Growth f/c 0.6% 0.5% 1.0	8% 4% 6%	
Quality Value High FCF Yield 1.2% -3.1% -1.9 Value Composite 0.8% 2.3% 3.1 Low Accruals -0.8% 0.4% -0.3 High Earnings Stability -0.2% 0.0% -0.2 Low Leverage 0.5% 2.2% 2.8 High Operating Efficiency -1.0% -0.6% -1.6 Quality Composite -1.6% -1.3% -3.0 High Internal Growth -1.5% 1.8% 0.3 High Dividend Growth -0.2% 1.2% 1.0 High Earnings Growth -1.3% 4.6% 3.2 High Long Term Growth f/c 0.6% 0.5% 1.0	8%	
Value Composite 0.8% 2.3% 3.1 Low Accruals -0.8% 0.4% -0.3 High Earnings Stability -0.2% 0.0% -0.2 High Profitability -1.2% -1.8% -2.9 Low Leverage 0.5% 2.2% 2.8 High Operating Efficiency -1.0% -0.6% -1.6 Quality Composite -1.6% -1.3% -3.0 High Internal Growth -1.5% 1.8% 0.3 High Dividend Growth -0.2% 1.2% 1.0 High Earnings Growth -1.3% 4.6% 3.2 High Long Term Growth f/c 0.6% 0.5% 1.0	5%	
Company Comp	9%	
Quality High Earnings Stability -0.2% 0.0% -0.2 High Profitability -1.2% -1.8% -2.9 Low Leverage 0.5% 2.2% 2.8 High Operating Efficiency -1.0% -0.6% -1.6 Quality Composite -1.6% -1.3% -3.0 High Internal Growth -1.5% 1.8% 0.3 High Dividend Growth -0.2% 1.2% 1.0 High Earnings Growth -1.3% 4.6% 3.2 High Long Term Growth f/c 0.6% 0.5% 1.0	1%	
Quality High Profitability -1.2% -1.8% -2.9 Low Leverage 0.5% 2.2% 2.8 High Operating Efficiency -1.0% -0.6% -1.6 Quality Composite -1.6% -1.3% -3.0 High Internal Growth -1.5% 1.8% 0.3 High Dividend Growth -0.2% 1.2% 1.0 High Earnings Growth -1.3% 4.6% 3.2 High Long Term Growth f/c 0.6% 0.5% 1.0	3%	
Low Leverage	2%	
High Operating Efficiency	9%	
Quality Composite -1.6% -1.3% -3.0 High Internal Growth -1.5% 18% 0.3 High Dividend Growth -0.2% 1.2% 1.0 High Earnings Growth -1.3% 4.6% 3.2 High Long Term Growth f/c 0.6% 0.5% 1.0	8%	
Growth High Internal Growth -1.5% 1.8% 0.3 High Dividend Growth -0.2% 1.2% 1.0 High Earnings Growth -1.3% 4.6% 3.2 High Long Term Growth f/c 0.6% 0.5% 1.0	6%	
Growth High Dividend Growth High Earnings Growth High Long Term Growth f/c 1 -0.2% Long Term Growth 1.2% Long Term Growth 1.3% Long Term Growth f/c 1 .2% Long Term Growth 1.2% Long Term Growth 1.2% Long Term Growth f/c	0%	
High Earnings Growth -1.3% 4.6% 3.2 High Long Term Growth f/c 0.6% 0.5% 1.0	3%	
High Earnings Growth -1.3% 4.6% 3.2 High Long Term Growth f/c 0.6% 0.5% 1.0		
	2%	
Growth Composite -1 3% 2 3% 0 0	0%	
	9%	
	1%	
Sentiment	3%	
Earnings Revision -0.6% 2.0% 1.4	4%	
	4%	
	2 %	
12M Price Momentum -1.4% -1.0% -2.4		
Small Cap 1.1% 0.5% 11.6		
Low Trading Liquidity -1.3% -3.5% -4.8		
Tachnicale	4%	
High DTC Short 1.0% 217% 3.7	7%	
	5%	
Low Volatility -1.6% -5.6% -7.1		
Low Beta -1.8% -4.0% -5.7	7%	

Source: FactSet, Morgan Stanley Research

Exhibit 42: Cumulative L/S Alpha since 2021 - Global EM



Source: FactSet, Morgan Stanley Research

Exhibit 43: Value Factors: Cumulative L/S Alpha since 2022 – Global EM




Exhibit 45: Quality Factors: Cumulative L/S Alpha since 2022 – Global EM




Source: FactSet, Morgan Stanley Research

Exhibit 47: Growth Factors: Cumulative L/S Alpha since 2022 – Global EM



Source: FactSet, Morgan Stanley Research

Exhibit 44: Value Factors: L/S Alpha Global EM



Source: FactSet, Morgan Stanley Research

Exhibit 46: Quality Factors: L/S Alpha Global EM



Source: FactSet, Morgan Stanley Research

Exhibit 48: Growth Factors: L/S Alpha Global EM



Exhibit 49: Sentiment Factors: Cumulative L/S Alpha since 2022 – Global EM




Exhibit 51: Other Factors: Cumulative L/S Alpha since 2022 – Global EM




Source: FactSet, Morgan Stanley Research

Exhibit 50: Sentiment Factors: L/S Alpha Global EM



Source: FactSet, Morgan Stanley Research

Exhibit 52: Other Factors: L/S Alpha Global EM



Source: FactSet, Morgan Stanley Research

China A – Factor Monitor

Exhibit 53: China A – Factor Performance Summary

As of:	3/22/2024			Chin	na A		
Category	Factor Description	Mar	MTD	Fe	b	YTD	
	Cheap P/B		-4.3%		-9.2%		13.2%
Deep Value	Cheap P/S		-2.4%		-5.7%		-8.0%
	Cheap P/E		-4.5%		0.6%		-3.9%
Defensive Value	High Total Yield		-6.4%		-2.1%		-8.4%
Current Value	Cheap Fwd P/E		-4.3%		-5.8%		-9.8%
Quality Value	High FCF Yield		-0.5%		0.0%		-0.5%
	Value Composite		-3.8%		-0.5%		-4.3%
	Low Accruals		1.2%		-2.5%		-1.3%
	High Earnings Stability		-1.4%		0.4%		-1.0%
Quality	High Profitability		-0.5%		4.5%		4.0%
Quality	Low Leverage		-0.7%		2.0%		1.3%
	High Operating Efficiency		1.0%		-1.9%		-0.9%
	Quality Composite		0.4%		0.5%		0.9%
	High Internal Growth		-2.6%		5.4%		2.6%
Growth	High Dividend Growth		0.3%		3.2%		3.5%
GIOWIII	High Earnings Growth		-0.4%		3.4%		3.0%
	High Long Term Growth f/c		1.3%		6.8%		8.1%
	Growth Composite		-1.4%		4.8%		3.3%
	1M Loser		1.9%		6.9%		9.0%
Sentiment	12M-1M Residual Return		6.9%		3.2%		10.4%
Sentiment	Earnings Revision		1.2%	Į.	-0.6%		0.5%
	Sales Revision		2.1%		0.0%		2.1%
	Sentiment Composite		5.0%		3.1%		8.2%
	12M Price Momentum		2.2%		0.0%		2.2%
	Small Cap		8.9%		-8.8%		-0.6%
Technicals	Low Trading Liquidity		-9.0%		-2.9%		11.6%
	Low Volatility		-9.7%		-10.1%		18.8%
	Low Beta		-5.1%		-8.1%		12.8%
Source: FactSet Morgan St	anlay Doggaroh						

Source: FactSet, Morgan Stanley Research

Exhibit 54: Cumulative L/S Alpha since 2021 - China A




Exhibit 55: Value Factors: Cumulative L/S Alpha since 2022 – China A




Exhibit 57: Quality Factors: – Cumulative L/S Alpha since 2022 – China A




Source: FactSet, Morgan Stanley Research

Exhibit 59: Growth Factors: Cumulative L/S Alpha since 2022 – China A



Source: FactSet, Morgan Stanley Research

Exhibit 56: Value Factors: L/S Alpha China A



Source: FactSet, Morgan Stanley Research

Exhibit 58: Quality Factors: L/S Alpha China A



Source: FactSet, Morgan Stanley Research

Exhibit 60: Growth Factors: L/S Alpha China A



Source: FactSet, Morgan Stanley Research

Exhibit 61: Sentiment Factors: Cumulative L/S Alpha since 2022 – China A



Exhibit 63: Other Factors: Cumulative L/S Alpha since 2022 – China A



Source: FactSet, Morgan Stanley Research

Exhibit 62: Sentiment Factors: L/S Alpha China A



Source: FactSet, Morgan Stanley Research

Exhibit 64: Other Factors: L/S Alpha China A



Japan – Factor Monitor

Exhibit 65: Japan – Factor Performance Summary

As of:	3/22/2024		Japan	
Category	Factor Description	Mar MTD	Feb	YTD
	Cheap P/B	5.8%	-1.5%	4.2%
Deep Value	Cheap P/S	5.6%	2.7%	2.8%
	Cheap P/E	3.7%	0.7%	4.5%
Defensive Value	High Total Yield	1.6%	0.0%	1.7%
Current Value	Cheap Fwd P/E	4.0%	-0.8%	3.1%
Quality Value	High FCF Yield	-0.9%	-1.0%	-1.9%
	Value Composite	0.5%	-2.9%	-2.5%
	Low Accruals	-0.3%	-1.0%	-1.2%
	High Earnings Stability	1.6%	-0.2%	1.4%
Quality	High Profitability	-2.9%	2.4%	-0.6%
	Low Leverage	-3.2%	0.2%	-2.9%
	High Operating Efficiency	1.6%	-1.7%	-0.1%
	Quality Composite	0.0%	0.8%	0.8%
	High Internal Growth	0.0%	3.0%	3.0%
Growth	High Dividend Growth	1.4%	-1.7%	-0.2%
arowin	High Earnings Growth	1.0%	3.2%	4.2%
	High Long Term Growth f/c	1.9%	-0.3%	1.6%
	Growth Composite	0.6%	0.4%	1.0%
	1M Loser	-2.6%	-6.1%	-8.5%
Sentiment	12M-1M Residual Return	0.9%	3.3%	4.3%
Sentiment	Earnings Revision	1.5%	1.8%	3.3%
	Sales Revision	-0.1%	3.6%	3.5%
	Sentiment Composite	0.0%	-0.7%	-0.6%
	12M Price Momentum	2.5%	6.2%	8.9%
	Small Cap	-0.2%	-9.0%	-9.2%
	Low Trading Liquidity	-0.3%	-3.1%	-3.4%
Technicals	High Short Ratio	-3.3%	-0.3%	-3.6%
recimicals	High DTC Short	-1.1%	-2.0%	-3.0%
	High Short Utilization	-2.3%	-2.9%	-5.1%
	Low Volatility	-0.5%	-4.2%	-4.7%
	Low Beta	3.4%	-1.4%	1.9%
Source: FactSet Morgan St	tanlay Daggarah			

Source: FactSet, Morgan Stanley Research

Exhibit 66: Cumulative L/S Alpha since 2022 – Japan



Source: FactSet, Morgan Stanley Research

Exhibit 67: Value Factors: Cumulative L/S Alpha since 2022 – Japan




Exhibit 69: Quality Factors: Cumulative L/S Alpha since 2022 – Japan




Source: FactSet, Morgan Stanley Research

Exhibit 71: Growth Factors: Cumulative L/S Alpha since 2022 – Japan



Source: FactSet, Morgan Stanley Research

Exhibit 68: Value Factors: L/S Alpha Japan



Source: FactSet, Morgan Stanley Research

Exhibit 70: Quality Factors: L/S Alpha Japan



Source: FactSet, Morgan Stanley Research

Exhibit 72: Growth Factors: L/S Alpha Japan




Exhibit 73: Sentiment Factors: Cumulative L/S Alpha since 2022 – Japan




Exhibit 75: Other Factors: Cumulative L/S Alpha since 2022 – Japan




Source: FactSet, Morgan Stanley Research

Exhibit 74: Sentiment Factors: L/S Alpha Japan



Source: FactSet, Morgan Stanley Research

Exhibit 76: Other Factors: L/S Alpha Japan



Source: FactSet, Morgan Stanley Research

India – Factor Monitor

Exhibit 77: India – Factor Performance Summary

As of:	3/22/2024	India						
Category	Factor Description	Mar MTD	Feb	YTD				
	Cheap P/B	-0.8%	-1.2%	-2.0%				
Deep Value	Cheap P/S	1.5%	-3.0%	-1.5%				
	Cheap P/E	-1.3%	0.4%	-0.9%				
Defensive Value	High Total Yield	-1.0%	-1.6%	-2.6%				
Current Value	Cheap Fwd P/E	-1.5%	-1.8%	-3.3%				
Quality Value	High FCF Yield	0.4%	-3.9%	-3.5%				
	Value Composite	-2.0%	2.3%	0.3%				
	Low Accruals	1.2%	2.2%	3.4%				
	High Earnings Stability	-2.3%	4.7%	2.3%				
Quality	High Profitability	-0.8%	-0.5%	-1.3%				
	Low Leverage	4.6%	-2.1%	2.4%				
	High Operating Efficiency	0.5%	1.0%	1.5%				
	Quality Composite	0.1%	-0.4%	-0.3%				
	High Internal Growth	0.4%	5.6%	6.0%				
Growth	High Dividend Growth	1.4%	3.3%	4.7%				
Growth	High Earnings Growth	-0.7%	9.3%	8.6%				
	High Long Term Growth f/c	1.4%	-1.4%	0.0%				
	Growth Composite	-0.1%	5.0%	4.9%				
	1M Loser	2.0%	-4.6%	-2.7%				
Sentiment	12M-1M Residual Return	-0.4%	3.2%	2.8%				
Sentiment	Earnings Revision	1.4%	5.0%	6.4%				
	Sales Revision	1.5%	-0.7%	0.8%				
	Sentiment Composite	1.6%	5.0%	6.7%				
	12M Price Momentum	-1.1%	6.6%	5.4%				
	Small Cap	-3.1%	-4.3%	-7.2%				
Technicals	Low Trading Liquidity	0.6%	3.0%	3.6%				
	Low Volatility	0.8%	0.3%	1.2%				
	Low Beta	0.2%	-0.4%	-0.2%				

Source: FactSet, Morgan Stanley Research

Exhibit 78: Cumulative L/S Alpha since 2022 - India



Exhibit 79: Value Factors: Cumulative L/S Alpha since 2022 – India



Exhibit 81: Quality Factors: Cumulative L/S Alpha since 2022 – India



Source: FactSet, Morgan Stanley Research

Exhibit 83: Growth Factors: Cumulative L/S Alpha since 2022 – India



Source: FactSet, Morgan Stanley Research

Exhibit 80: Value Factors: L/S Alpha India



Source: FactSet, Morgan Stanley Research

Exhibit 82: Quality Factors: L/S Alpha India



Source: FactSet, Morgan Stanley Research

Exhibit 84: Growth Factors: L/S Alpha India



Source: FactSet, Morgan Stanley Research

Exhibit 85: Sentiment Factors: Cumulative L/S Alpha since 2022 – India




Exhibit 87: Other Factors: Cumulative L/S Alpha since 2022 – India



Source: FactSet, Morgan Stanley Research

Exhibit 86: Sentiment Factors: L/S Alpha India



Source: FactSet, Morgan Stanley Research

Exhibit 88: Other Factors: L/S Alpha India



ASEAN – Factor Monitor

Exhibit 89: ASEAN – Factor Performance Summary

As of:	3/22/2024		ASEAN	
Category	Factor Description	Mar MTD	Feb	YTD
	Cheap P/B	0.0%	0.0%	0.0%
Deep Value	Cheap P/S	-0.8%	6.7%	5.8%
	Cheap P/E	1.7%	1.3%	3.0%
Defensive Value	High Total Yield	0.7%	0.1%	0.8%
Current Value	Cheap Fwd P/E	1.3%	1.7%	2.9%
Quality Value	High FCF Yield	2.6%	3.5%	6.1%
	Value Composite	1.5%	-0.9%	0.6%
	Low Accruals	0.3%	-1.1%	-0.8%
	High Earnings Stability	-1.9%	2.0%	0.0%
Quality	High Profitability	2.1%	-0.5%	1.5%
	Low Leverage	0.3%	3.4%	3.7%
	High Operating Efficiency	-0.5%	-0.6%	-1.1%
	Quality Composite	1.7%	2.5%	4.2%
	High Internal Growth	0.9%	4.6%	5.6%
Growth	High Dividend Growth	1.8%	0.8%	2.7%
G. G. W.	High Earnings Growth	-0.3%	0.3%	0.1%
	High Long Term Growth f/c	-0.3%	9.1%	8.8%
	Growth Composite	2.4%	-0.2%	2.2%
	1M Loser	-0.6%		
Sentiment	12M-1M Residual Return	-0.2%	0.4%	0.2%
Common	Earnings Revision	1.0%	0.3%	1.4%
	Sales Revision	-1.5%	1.8%	0.3%
	Sentiment Composite	-1.4%	-1.2%	-2.6%
	12M Price Momentum	-0.7%	1.8%	1.1%
	Small Cap	-1.1%	-1.0%	-2.0%
	Low Trading Liquidity	-2.1%	2.9%	0.7%
Technicals	High Short Ratio	-1.8%	-1.3%	-3.1%
	High DTC Short	-2.4%	-2.4%	
	High Short Utilization	-2.6%	-0.3%	-2.9%
	Low Volatility	-0.4%	1.1%	0.7%
	Low Beta	-0.1%	1.0%	0.9%
Course: FootCat Margan C				

Source: FactSet, Morgan Stanley Research

Exhibit 90: Cumulative L/S Alpha since 2022 - ASEAN



Source: FactSet, Morgan Stanley Research

Exhibit 91: Value Factors: Cumulative L/S Alpha since 2022 – ASEAN



Exhibit 93: Quality Factors: Cumulative L/S Alpha since 2022 – ASEAN




Source: FactSet, Morgan Stanley Research

Exhibit 95: Growth Factors: Cumulative L/S Alpha since 2022 – ASEAN




Source: FactSet, Morgan Stanley Research

Exhibit 92: Value Factors: L/S Alpha ASEAN



Source: FactSet, Morgan Stanley Research

Exhibit 94: Quality Factors: L/S Alpha ASEAN



Source: FactSet, Morgan Stanley Research

Exhibit 96: Growth Factors: L/S Alpha ASEAN




Exhibit 97: Sentiment Factors: Cumulative L/S Alpha since 2022 – ASEAN




Exhibit 99: Other Factors: Cumulative L/S Alpha since 2022 – ASEAN




Source: FactSet, Morgan Stanley Research

Exhibit 98: Sentiment Factors: L/S Alpha ASEAN



Source: FactSet, Morgan Stanley Research

Exhibit 100: Other Factors: L/S Alpha ASEAN



Source: FactSet, Morgan Stanley Research

Factor Performance by Market

Exhibit 101: YTD Factor Performance Summary – by MSCI Market

As of:	3/22/2024						Asia	Pacific ex J	lapan					
Category	Factor Description	YTD	Country Neutral	Australia	China	Hong Kong	India	Indonesia	Korea	Malaysia	Philippines	Singapore	Taiwan	Thailand
	Cheap P/B	1.7%	4.7%	-2.9%	3.4%	-6.4%	5.5%	2.1%	17.9%	5.0%	2.4%	-15.4%	6.4%	-0.5%
Deep Value	Cheap P/S	1.7%	3.6%	-6.9%	5.0%	2.8%	2.9%	11.4%	0.3%	4.4%	-7.1%	1.5%	8.1%	-4.0%
	Cheap P/E	7.2%	5.7%	-4.6%	6.3%	4.1%	4.8%	18.7%	11.1%	0.5%	15.6%	5.5%	18.7%	-1.9%
Defensive Value	High Total Yield	3.1%	5.3%	-11.2%	5.4%	-2.9%	2.2%	14.9%	22.0%	1.3%	11.3%	0.9%	9.6%	-5.9%
Current Value	Cheap Fwd P/E	5.9%	7.6%	-5.8%	6.7%	4.3%	1.6%	19.5%	25.3%	1.3%	20.2%	3.7%	16.8%	-5.0%
Quality Value	High FCF Yield	0.5%	3.8%	-6.1%	4.7%	13.5%	-1.6%	16.3%	8.2%	-1.2%	2.4%	-9.5%	11.9%	2.0%
	Value Composite	4.3%	5.3%	-11.3%	5.7%	7.2%	7.2%	12.0%	7.8%	-2.7%	3.2%	-1.2%	15.0%	-5.1%
	Low Accruals	-0.8%	0.6%	-11.6%	1.0%	4.4%	10.0%	-3.0%	-1.6%	-2.5%	9.4%	-5.7%	0.8%	-8.2%
	High Earnings Stability	4.5%	6.8%	2.2%	9.0%	14.2%	-1.8%	-0.7%	11.2%	-6.6%	4.2%	4.8%	11.5%	-12.1%
Quality	High Profitability	4.0%	2.2%	0.4%	3.9%	-2.2%	-3.1%	22.9%	-8.6%	-2.9%	5.1%	16.8%	4.4%	-9.3%
	Low Leverage	1.4%	3.3%	-5.6%	4.1%	11.4%	-3.1%	15.6%	-0.5%	1.1%	-6.1%	13.6%	-0.7%	4.0%
	High Operating Efficiency	-1.0%	3.0%	4.8%	6.8%	11.3%	-0.8%	-9.4%	-13.4%	-6.0%	6.8%	6.9%	15.3%	-11.9%
	Quality Composite	1.3%	4.9%	-2.2%	9.0%	18.7%	-3.6%	10.9%	-0.3%	-6.5%	18.3%	3.8%	-1.5%	-10.2%
	High Internal Growth	2.7%	0.8%	4.0%	-2.1%	6.6%	2.8%	16.3%	4.5%	-2.0%	7.5%	18.5%	6.0%	0.0%
Growth	High Dividend Growth	2.3%	4.2%	6.3%	3.1%	3.9%	-0.2%	6.5%	0.0%	-0.5%	11.6%	1.9%	9.9%	1.4%
alowiii	High Earnings Growth	8.5%	6.6%	6.9%	3.6%	0.4%	14.9%	-8.0%	17.9%	4.8%	3.0%	2.4%	14.4%	11.1%
	High Long Term Growth f/c	3.6%	-0.7%	13.2%	0.2%	-13.5%	1.1%	22.8%	-8.0%	8.5%	0.0%	-3.1%	3.2%	4.8%
-	Growth Composite	1.9%	4.1%	12.5%	1.5%	-5.1%	2.9%	14.4%	-5.5%	-2.4%	2.0%	6.2%	11.7%	2.8%
	1M Loser	-6.8%	-2.0%	4.2%	-1.4%	-2.9%	-7.8%	-1.2%	-19.7%	-0.8%	18.0%	-4.4%	3.0%	-4.0%
Sentiment	12M-1M Residual Return	12.8%	12.6%	9.0%	12.8%	14.0%	11.7%	14.9%	21.1%	7.8%	14.8%	1.0%	14.3%	8.1%
Continuent	Earnings Revision	9.2%	7.8%	8.8%	9.7%	-4.1%	11.1%	3.2%	18.5%	-1.4%	-7.0%	2.6%	2.3%	0.9%
	Sales Revision	5.6%	3.7%	5.3%	6.7%	8.3%	-0.5%	-9.8%	6.2%	-1.1%	10.5%	-2.5%	-2.9%	-3.7%
-	Sentiment Composite	10.7%	10.3%	8.7%	11.7%	11.7%	8.4%	10.0%	9.1%	2.6%	6.7%	-4.4%	9.7%	-0.1%
	12M Price Momentum	11.3%	11.6%	7.8%	11.8%	14.3%	13.2%	18.9%	23.5%	4.2%	11.1%	6.4%	12.2%	-1.0%
Others	Small Cap	-3.3%	-4.0%	-2.4%	-5.4%	-3.5%	-7.3%	-14.1%	-9.2%	5.2%	3.9%	-25.0%	-4.7%	-4.7%
Culois	Low Volatility	4.2%	1.4%	5.3%	1.1%	-2.4%	-8.3%	19.2%	15.8%	-2.6%	18.3%	4.4%	-1.8%	-1.9%
-	Low Beta	3.3%	2.1%	7.2%	1.9%	-5.1%	-7.9%	-4.5%	14.9%	-0.4%	-4.1%	15.0%	7.4%	-5.3%

Factor Performance by Sector

Exhibit 102: YTD Factor Performance Summary – by GICS Sector

As of: 3/22/2024		Asia Pacific ex Japan												
Category	Factor Description	YTD	Sector Neutral	Energy	Materials	Industrials	Cons. Disc.	Cons. Staple	Health Care	Financials	Info Tech	Comm. Services	Utilities	Real Estate
Deep Value	Cheap P/B	1.7%	3.1%	1.0%	3.0%	-2.2%	8.9%	1.5%	-6.0%	18.1%	-0.1%	-0.4%	3.9%	-15.9%
	Cheap P/S	1.7%	1.0%	2.1%	6.6%	-1.6%	4.5%	0.2%	-0.5%	0.0%	2.4%	-4.4%	5.4%	-16.9%
	Cheap P/E	7.2%	5.6%	17.7%	7.8%	3.2%	12.7%	7.8%	-0.8%	14.5%	6.5%	-2.7%	-0.8%	-11.4%
Defensive Value	High Total Yield	3.1%	2.8%	-0.1%	0.8%	3.1%	0.9%	6.6%	3.5%	13.5%	6.2%	-7.6%	-6.4%	-6.7%
Current Value	Cheap Fwd P/E	5.9%	6.1%	8.4%	12.5%	0.4%	10.0%	2.8%	-0.2%	14.8%	8.6%	-11.2%	8.3%	-15.0%
Quality Value	High FCF Yield	0.5%	3.9%	-3.4%	10.1%	6.0%	4.9%	2.2%	6.6%	0.0%	5.6%	5.6%	-6.6%	-7.3%
	Value Composite	4.3%	7.0%	17.4%	5.5%	1.0%	9.2%	6.7%	3.4%	15.1%	9.5%	-4.7%	-1.1%	-16.6%
	Low Accruals	-0.8%	0.6%	0.1%	-3.8%	-0.2%	1.1%	-8.4%	9.5%	0.0%	6.5%	-6.4%	-2.7%	5.4%
	High Earnings Stability	4.5%	5.4%	5.1%	2.1%	9.0%	5.3%	4.2%	0.3%	6.9%	13.5%	-11.0%	-2.3%	6.3%
Quality	High Profitability	4.0%	3.5%	7.8%	-4.0%	9.3%	4.4%	2.0%	-0.3%	4.5%	5.4%	-7.0%	-7.7%	0.4%
	Low Leverage	1.4%	2.2%	-0.9%	1.2%	11.2%	-2.3%	2.4%	-1.9%	0.0%	0.0%	8.1%	-5.6%	0.8%
	High Operating Efficiency	-1.0%	4.0%	8.4%	-0.6%	2.0%	6.9%	-1.8%	15.7%	4.2%	3.8%	4.1%	4.7%	-6.0%
	Quality Composite	1.3%	6.2%	4.6%	2.6%	8.0%	8.8%	-1.0%	8.5%	7.8%	6.6%	-7.4%	-5.7%	9.0%
	High Internal Growth	2.7%	0.8%	13.6%	3.8%	7.4%	6.8%	-1.3%	-9.3%	-1.5%	-1.4%	-1.3%	-3.3%	-1.4%
Growth	High Dividend Growth	2.3%	3.7%	0.4%	3.3%	0.8%	1.6%	-1.2%	1.2%	6.3%	3.1%	6.2%	1.1%	9.1%
Ciowaii	High Earnings Growth	8.5%	3.9%	-4.1%	4.0%	8.0%	7.5%	-5.4%	7.2%	5.1%	9.8%	2.6%	1.4%	5.5%
	High Long Term Growth f/c	3.6%	-3.6%	3.6%	-5.0%	-15.9%	17.3%	-1.2%	-4.6%	-14.5%	-6.6%	2.0%	5.9%	2.7%
-	Growth Composite	1.9%	2.6%	8.4%	2.0%	-2.2%	8.8%	0.2%	0.1%	3.2%	7.5%	1.7%	-1.7%	2.6%
	1M Loser	-6.8%	-3.3%	-8.3%	-1.6%	1.5%	-3.4%	-6.4%	-14.3%	-6.3%	-6.5%	-0.5%	-4.1%	-8.1%
Sentiment	12M-1M Residual Return	12.8%	11.4%	8.8%	8.7%	11.2%	22.4%	5.0%	18.6%	5.7%	20.9%	3.9%	7.4%	11.4%
Sentiment	Earnings Revision	9.2%	9.1%	9.0%	8.0%	6.0%	17.1%	3.2%	10.0%	0.2%	23.8%	1.4%	6.0%	8.6%
	Sales Revision	5.6%	4.8%	-1.5%	5.1%	9.0%	13.3%	1.9%	1.7%	0.1%	6.6%	2.4%	4.2%	10.1%
	Sentiment Composite	10.7%	10.7%	8.0%	9.1%	14.1%	19.5%	5.3%	8.3%	1.0%	15.9%	14.6%	10.0%	19.6%
Others	12M Price Momentum	11.3%	10.5%	17.2%	8.1%	10.0%	13.4%	4.1%	25.3%	5.1%	11.2%	-8.6%	6.9%	15.9%
	Small Cap	-3.3%	-4.1%	-6.8%	-3.9%	-5.0%	-6.0%	-3.4%	-0.9%	0.0%	-8.2%	-3.7%	-3.7%	-5.8%
	Low Volatility	4.2%	1.2%	-5.6%	1.2%	0.1%	5.6%	7.2%	13.8%	5.6%	-11.5%	-8.5%	-1.2%	6.5%
	Low Beta	3.3%	1.8%	2.2%	-1.1%	1.8%	3.4%	3.1%	15.6%	2.5%	-6.5%	-0.8%	0.4%	12.6%

Source: FactSet, MSCI, Morgan Stanley Research

Appendix – Factor Definitions

Exhibit 103: Morgan Stanley Factor Definitions in Detail

Style Grou	p & Factor Name	Definition					
Style Grou	Cheap P/B	Last reported book value of common equity / current market cap					
	Cheap P/S	Trailing 12m total revenue / current market cap					
	Cheap P/E	Trailing 12m earnings / current market cap					
	Cheap Fwd P/E	IBES median time-weighted NTM EPS Estimate divided by Price					
Value	High Total Yield	Dividend Yield plus Buyback Yield					
value	High FCF Composite	Average of Z-score of FCF-to-EV and FCF Yield					
	Free Cash Flow Yield	Trailing 12-month Free Cash Flow (operating cash flow - net capex) / current market cap					
	Free Cash Flow / EV	Trailing 12-month Free Cash Flow (operating cash flow - net capex) / EV					
	MS Value Composite	Average of Z-score of Free Cash Flow Sub Composite, 'Tangible Book/Price', Earnings Yield & Total Yield					
-	Dividend Growth	Y/Y Change in DPS (percent change of the latest reported 12m DPS compared to what it was 1 year ago)					
	Long Term Growth Forecast	IBES mean 5-Year EPS growth forecast					
Growth	Y/Y Earnings Growth	Percentage change in the trailing 12-month Net Income over the last 1 year. Not used if Net Income 1-year ago were negative.					
Ciontii	Internal Growth	Retention rate times ROE					
	MS Growth Composite	Average of Z-score of Internal Growth, 'Y/Y Earnings Growth', 'Y/Y Dividend Growth' & 'Long Term Growth Forecast'					
-	1M Reversal	Reciprocal of 1m trailing Total Return					
	12-1m Residual Momentum	12m Residual Momentum lagged by 1m					
Sentiment	Earnings Revision Sub Composite	Average of Z-score of 'Earnings Revisions Breadth' & 'Earnings Estimate Revisions'					
	Earnings Estimate Revisions	Time-Weighted 1m change in the IBES median EPS estimate scaled by price					
	Earnings Revisions Breadth	Median Time-Weighted NTM EPS Revisions					
	Sales Revision Sub Composite	Average of Z-score of 'Sales Revisions Breadth' & 'Sales Estimate Revisions'					
	Sales Estimate Revisions	Time-Weighted 1m change in the IBES median Sales estimate scaled by market cap					
	Sales Revisions Breadth	Median Time-Weighted NTM Sales Revisions					
	MS Sentiment Composite	Average of Z-score of 'Earnings Revision Sub Composite', 'Sales Revision Sub Composite', '12m-1m Residual Momentum' & '1m Reversal'					
	Accruals Sub Composite	Average of Z-score of Accruals & 'Short-term Accruals'					
	Accruals Sub Composite Low Accruals	Average of Z-score of Accruals & 'Short-term Accruals' Y/Y change in Net Operating Assets /total assets a year ago, low values are favored					
	•						
	Low Accruals	Y/Y change in Net Operating Assets /total assets a year ago, low values are favored					
	Low Accruals	Y/Y change in Net Operating Assets /total assets a year ago, low values are favored Y/Y change in Current Net Operating Assets /Average Assets, low values are favored					
	Low Accruals Low ST Accruals Earnings Stability Sub Composite	Y/Y change in Net Operating Assets /total assets a year ago, low values are favored Y/Y change in Current Net Operating Assets /Average Assets, low values are favored Average of Z-score of 'Estimate Dispersion', 'ROE Variability' & 'Sales Stability'					
	Low Accruals Low ST Accruals Earnings Stability Sub Composite Low Estimate Dispersion	Y/Y change in Net Operating Assets /total assets a year ago, low values are favored Y/Y change in Current Net Operating Assets /Average Assets, low values are favored Average of Z-score of 'Estimate Dispersion', 'ROE Variability' & 'Sales Stability' Std deviation of IBES EPS estimates divided by absolute value of mean IBES estimate, low values are favored					
	Low Accruals Low ST Accruals Earnings Stability Sub Composite Low Estimate Dispersion Low ROE Variability	Y/Y change in Net Operating Assets /total assets a year ago, low values are favored Y/Y change in Current Net Operating Assets /Average Assets, low values are favored Average of Z-score of 'Estimate Dispersion', 'ROE Variability' & 'Sales Stability' Std deviation of IBES EPS estimates divided by absolute value of mean IBES estimate, low values are favored 5-year std deviation of ROE divided by 5-year absolute mean of ROE, low values are favored					
	Low Accruals Low ST Accruals Earnings Stability Sub Composite Low Estimate Dispersion Low ROE Variability Sales Stability	Y/Y change in Net Operating Assets /total assets a year ago, low values are favored Y/Y change in Current Net Operating Assets /Average Assets, low values are favored Average of Z-score of 'Estimate Dispersion', 'ROE Variability' & 'Sales Stability' Std deviation of IBES EPS estimates divided by absolute value of mean IBES estimate, low values are favored 5-year std deviation of ROE divided by 5-year absolute mean of ROE, low values are favored 5-year std deviation of Y/Y Sales Growth					
Quality	Low Accruals Low ST Accruals Earnings Stability Sub Composite Low Estimate Dispersion Low ROE Variability Sales Stability Profitability Sub Composite	Y/Y change in Net Operating Assets /total assets a year ago, low values are favored Y/Y change in Current Net Operating Assets /Average Assets, low values are favored Average of Z-score of 'Estimate Dispersion', 'ROE Variability' & 'Sales Stability' Std deviation of IBES EPS estimates divided by absolute value of mean IBES estimate, low values are favored 5-year std deviation of ROE divided by 5-year absolute mean of ROE, low values are favored 5-year std deviation of Y/Y Sales Growth Average of Z-score of ROE, 'Gross Profit-to-Assets', 'Gross Margin' & 'Operating Leverage'					
Quality	Low Accruals Low ST Accruals Earnings Stability Sub Composite Low Estimate Dispersion Low ROE Variability Sales Stability Profitability Sub Composite Gross Profit / Assets Gross Margin Operating Leverage	Y/Y change in Net Operating Assets /total assets a year ago, low values are favored Y/Y change in Current Net Operating Assets /Average Assets, low values are favored Average of Z-score of 'Estimate Dispersion', 'ROE Variability' & 'Sales Stability' Std deviation of IBES EPS estimates divided by absolute value of mean IBES estimate, low values are favored 5-year std deviation of ROE divided by 5-year absolute mean of ROE, low values are favored 5-year std deviation of Y/Y Sales Growth Average of Z-score of ROE, 'Gross Profit-to-Assets', 'Gross Margin' & 'Opeating Leverage' (Trailing 12m Revenue - COGS) / total assets from 12m ago Trailing 12m revenue minus COGS / trailing 12m revenue 12m change in EBIT / 12m change in Sales					
Quality	Low Accruals Low ST Accruals Earnings Stability Sub Composite Low Estimate Dispersion Low ROE Variability Sales Stability Profitability Sub Composite Gross Profit / Assets Gross Margin Operating Leverage Leverage Sub Composite	Y/Y change in Net Operating Assets /total assets a year ago, low values are favored Y/Y change in Current Net Operating Assets /Average Assets, low values are favored Average of Z-score of 'Estimate Dispersion', 'ROE Variability' & 'Sales Stability' Std deviation of IBES EPS estimates divided by absolute value of mean IBES estimate, low values are favored 5-year std deviation of ROE divided by 5-year absolute mean of ROE, low values are favored 5-year std deviation of Y/Y Sales Growth Average of Z-score of ROE, 'Gross Profit-to-Assets', 'Gross Margin' & 'Opeating Leverage' (Trailing 12m Revenue - COGS) / total assets from 12m ago Trailing 12m revenue minus COGS / trailing 12m revenue 12m change in EBIT / 12m change in Sales Average of Z-score of 'Cash Flow Coverage' & 'Cash Flow-to-Debt'					
Quality	Low Accruals Low ST Accruals Earnings Stability Sub Composite Low Estimate Dispersion Low ROE Variability Sales Stability Profitability Sub Composite Gross Profit / Assets Gross Margin Operating Leverage Leverage Sub Composite Cash Flow Coverage	Y/Y change in Net Operating Assets /total assets a year ago, low values are favored Y/Y change in Current Net Operating Assets /Average Assets, low values are favored Average of Z-score of 'Estimate Dispersion', 'ROE Variability' & 'Sales Stability' Std deviation of IBES EPS estimates divided by absolute value of mean IBES estimate, low values are favored 5-year std deviation of ROE divided by 5-year absolute mean of ROE, low values are favored 5-year std deviation of Y/Y Sales Growth Average of Z-score of ROE, 'Gross Profit-to-Assets', 'Gross Margin' & 'Opeating Leverage' (Trailling 12m Revenue - COGS) / total assets from 12m ago Trailling 12m revenue minus COGS/ trailling 12m revenue 12m change in EBIT / 12m change in Sales Average of Z-score of 'Cash Flow Coverage' & 'Cash Flow-to-Debt' (Operating Cash Flows+Interest Expense)/Interest Expense					
Quality	Low Accruals Low ST Accruals Earnings Stability Sub Composite Low Estimate Dispersion Low ROE Variability Sales Stability Profitability Sub Composite Gross Profit / Assets Gross Margin Operating Leverage Leverage Sub Composite Cash Flow Coverage Cash Flow-to-Debt	Y/Y change in Net Operating Assets /total assets a year ago, low values are favored Y/Y change in Current Net Operating Assets /Average Assets, low values are favored Average of Z-score of 'Estimate Dispersion', 'ROE Variability' & 'Sales Stability' Sid deviation of IBES EPS estimates divided by absolute value of mean IBES estimate, low values are favored 5-year std deviation of ROE divided by 5-year absolute mean of ROE, low values are favored 5-year std deviation of Y/Y Sales Growth Average of Z-score of ROE, 'Gross Profit-to-Assets', 'Gross Margin' & 'Opeating Leverage' (Trailing 12m Revenue - COGS) / total assets from 12m ago Trailing 12m revenue minus COGS / trailing 12m revenue 12m change in EBIT / 12m change in Sales Average of Z-score of 'Cash Flow Coverage' & 'Cash Flow-to-Debt' (Operating Cash Flows+Interest Expense)/Interest Expense Operating Cash Flows / Total Debt					
Quality	Low Accruals Low ST Accruals Earnings Stability Sub Composite Low Estimate Dispersion Low ROE Variability Sales Stability Profitability Sub Composite Gross Profit / Assets Gross Margin Operating Leverage Leverage Sub Composite Cash Flow Coverage Cash Flow-to-Debt Operational Efficiency Sub Composite	Y/Y change in Net Operating Assets /total assets a year ago, low values are favored Y/Y change in Current Net Operating Assets /Average Assets, low values are favored Average of Z-score of 'Estimate Dispersion', 'ROE Variability' & 'Sales Stability' Std deviation of IBES EPS estimates divided by absolute value of mean IBES estimate, low values are favored 5-year std deviation of ROE divided by 5-year absolute mean of ROE, low values are favored 5-year std deviation of Y/Y Sales Growth Average of Z-score of ROE, 'Gross Profit-to-Assets', 'Gross Margin' & 'Opeating Leverage' (Trailing 12m Revenue - COGS) / total assets from 12m ago Trailing 12m revenue minus COGS / trailing 12m revenue 12m change in EBIT / 12m change in Sales Average of Z-score of 'Cash Flow Coverage' & 'Cash Flow-to-Debt' (Operating Cash Flows+Interest Expense)/Interest Expense Operating Cash Flows / Total Debt Average of Z-score of 'Capex-to-Sales', 'Y/Y Change in Inventory/Sales' & 'Y/Y Change in Num of Employees'					
Quality	Low Accruals Low ST Accruals Earnings Stability Sub Composite Low Estimate Dispersion Low ROE Variability Sales Stability Profitability Sub Composite Gross Profit / Assets Gross Margin Operating Leverage Leverage Sub Composite Cash Flow Coverage Cash Flow-to-Debt Operational Efficiency Sub Composite Low Capex/Sales	Y/Y change in Net Operating Assets /total assets a year ago, low values are favored Y/Y change in Current Net Operating Assets /Average Assets, low values are favored Average of Z-score of 'Estimate Dispersion', 'ROE Variability' & 'Sales Stability' Sid deviation of IBES EPS estimates divided by absolute value of mean IBES estimate, low values are favored 5-year std deviation of ROE divided by 5-year absolute mean of ROE, low values are favored 5-year std deviation of Y/Y Sales Growth Average of Z-score of ROE, 'Gross Profit-to-Assets', 'Gross Margin' & 'Opeating Leverage' (Trailing 12m Revenue - COGS) / total assets from 12m ago Trailing 12m revenue minus COGS / trailing 12m revenue 12m change in EBIT / 12m change in Sales Average of Z-score of 'Cash Flow Coverage' & 'Cash Flow-to-Debt' (Operating Cash Flows / Total Debt Average of Z-score of 'Capex-to-Sales', 'Y/Y Change in Inventory/Sales' & 'Y/Y Change in Num of Employees' Trailing 12m net capital expenditure / trailing 12m revenue, low values are favored					
Quality	Low Accruals Low ST Accruals Earnings Stability Sub Composite Low Estimate Dispersion Low ROE Variability Sales Stability Profitability Sub Composite Gross Profit / Assets Gross Margin Operating Leverage Leverage Sub Composite Cash Flow Coverage Cash Flow-to-Debt Operational Efficiency Sub Composite Low Capex/Sales Y/Y Change in Inventory/Sales	Y/Y change in Net Operating Assets /total assets a year ago, low values are favored Y/Y change in Current Net Operating Assets /Average Assets, low values are favored Average of Z-score of 'Estimate Dispersion', 'ROE Variability' & 'Sales Stability' Sid deviation of IBES EPS estimates divided by absolute value of mean IBES estimate, low values are favored 5-year std deviation of ROE divided by 5-year absolute mean of ROE, low values are favored 5-year std deviation of Y/Y Sales Growth Average of Z-score of ROE, 'Gross Profit-to-Assets', 'Gross Margin' & 'Opeating Leverage' (Trailing 12m Revenue - COGS) / total assets from 12m ago Trailing 12m revenue minus COGS / trailing 12m revenue 12m change in EBIT / 12m change in Sales Average of Z-score of 'Cash Flow Coverage' & 'Cash Flow-to-Debt' (Operating Cash Flows / Total Debt Average of Z-score of 'Capex-to-Sales', 'Y/Y Change in Inventory/Sales' & 'Y/Y Change in Num of Employees' Trailing 12m net capital expenditure / trailing 12m revenue, low values are favored Difference between the most recent Inventory/Sales and Inventory/Sales from 12m ago					
Quality	Low Accruals Low ST Accruals Earnings Stability Sub Composite Low Estimate Dispersion Low ROE Variability Sales Stability Profitability Sub Composite Gross Profit / Assets Gross Margin Operating Leverage Leverage Sub Composite Cash Flow Coverage Cash Flow Coverage Cash Flow Coverage Cash Flow Coverage Cycle Composite Low Capex/Sales Y/Y Change in Inventory/Sales Low Y/Y Change in Num of Employees	Y/Y change in Net Operating Assets /total assets a year ago, low values are favored Y/Y change in Current Net Operating Assets /Average Assets, low values are favored Average of Z-score of 'Estimate Dispersion', 'ROE Variability' & 'Sales Stability' Std deviation of IBES EPS estimates divided by absolute value of mean IBES estimate, low values are favored 5-year std deviation of ROE divided by 5-year absolute mean of ROE, low values are favored 5-year std deviation of Y/Y Sales Growth Average of Z-score of ROE, 'Gross Profit-to-Assets', 'Gross Margin' & 'Opeating Leverage' (Trailing 12m Revenue - COGS) / total assets from 12m ago Trailing 12m revenue minus COGS / trailing 12m revenue 12m change in EBIT / 12m change in Sales Average of Z-score of 'Cash Flow Coverage' & 'Cash Flow-to-Debt' (Operating Cash Flows+Interest Expense)/Interest Expense Operating Cash Flows / Total Debt Average of Z-score of 'Capex-to-Sales', 'Y/Y Change in Inventory/Sales' & 'Y/Y Change in Num of Employees' Trailing 12m net capital expenditure / trailing 12m revenue, low values are favored Difference between the most recent Inventory/Sales and Inventory/Sales from 12m ago Y/Y percent change in number of employees					
Quality	Low Accruals Low ST Accruals Earnings Stability Sub Composite Low Estimate Dispersion Low ROE Variability Sales Stability Profitability Sub Composite Gross Profit / Assets Gross Margin Operating Leverage Leverage Sub Composite Cash Flow Coverage Cash Flow-to-Debt Operational Efficiency Sub Composite Low Capex/Sales Y/Y Change in Inventory/Sales	Y/Y change in Net Operating Assets /total assets a year ago, low values are favored Y/Y change in Current Net Operating Assets /Average Assets, low values are favored Average of Z-score of 'Estimate Dispersion', 'ROE Variability' & 'Sales Stability' Std deviation of IBES EPS estimates divided by absolute value of mean IBES estimate, low values are favored 5-year std deviation of ROE divided by 5-year absolute mean of ROE, low values are favored 5-year std deviation of Y/Y Sales Growth Average of Z-score of ROE, 'Gross Profit-to-Assets', 'Gross Margin' & 'Opeating Leverage' (Trailing 12m Revenue - COGS) / total assets from 12m ago Trailing 12m revenue minus COGS / trailing 12m revenue 12m change in EBIT / 12m change in Sales Average of Z-score of 'Cash Flow Coverage' & 'Cash Flow-to-Debt' (Operating Cash Flows+Interest Expense)/Interest Expense Operating Cash Flows / Total Debt Average of Z-score of 'Capex-to-Sales', 'Y/Y Change in Inventory/Sales' & 'Y/Y Change in Num of Employees' Trailing 12m net capital expenditure / trailing 12m revenue, low values are favored Difference between the most recent Inventory/Sales and Inventory/Sales from 12m ago Y/Y percent change in number of employees Average of Z-score of 'Accruals Sub Composite', 'Earnings Stability Sub Composite', 'Profitability Sub Composite', 'Leverage Sub Composite' &					
Quality	Low Accruals Low ST Accruals Earnings Stability Sub Composite Low Estimate Dispersion Low ROE Variability Sales Stability Profitability Sub Composite Gross Profit / Assets Gross Margin Operating Leverage Leverage Sub Composite Cash Flow Coverage Cash Flow Coverage Cash Flow Coverage Cash Flow Coverage Cycle Composite Low Capex/Sales Y/Y Change in Inventory/Sales Low Y/Y Change in Num of Employees	Y/Y change in Net Operating Assets /total assets a year ago, low values are favored Y/Y change in Current Net Operating Assets /Average Assets, low values are favored Average of Z-score of 'Estimate Dispersion', 'ROE Variability' & 'Sales Stability' Std deviation of IBES EPS estimates divided by absolute value of mean IBES estimate, low values are favored 5-year std deviation of ROE divided by 5-year absolute mean of ROE, low values are favored 5-year std deviation of Y/Y Sales Growth Average of Z-score of ROE, 'Gross Profit-to-Assets', 'Gross Margin' & 'Opeating Leverage' (Trailing 12m Revenue - COGS) / total assets from 12m ago Trailing 12m revenue minus COGS / trailing 12m revenue 12m change in EBIT / 12m change in Sales Average of Z-score of 'Cash Flow Coverage' & 'Cash Flow-to-Debt' (Operating Cash Flows+Interest Expense)/Interest Expense Operating Cash Flows / Total Debt Average of Z-score of 'Capex-to-Sales', 'Y/Y Change in Inventory/Sales' & 'Y/Y Change in Num of Employees' Trailing 12m net capital expenditure / trailing 12m revenue, low values are favored Difference between the most recent Inventory/Sales and Inventory/Sales from 12m ago Y/Y percent change in number of employees					
	Low Accruals Low ST Accruals Earnings Stability Sub Composite Low Estimate Dispersion Low ROE Variability Sales Stability Profitability Sub Composite Gross Profit / Assets Gross Margin Operating Leverage Leverage Sub Composite Cash Flow Coverage Cash Flow Coverage Cash Flow-to-Debt Operational Efficiency Sub Composite Low Capex/Sales Y/Y Change in Inventory/Sales Low Y/Y Change in Num of Employees MS Quality Composite	Y/Y change in Net Operating Assets /total assets a year ago, low values are favored Y/Y change in Current Net Operating Assets /Average Assets, low values are favored Average of Z-score of 'Estimate Dispersion', 'ROE Variability' & 'Sales Stability' Std deviation of IBES EPS estimates divided by absolute value of mean IBES estimate, low values are favored 5-year std deviation of ROE divided by 5-year absolute mean of ROE, low values are favored 5-year std deviation of Y/Y Sales Growth Average of Z-score of ROE, 'Gross Profit-to-Assets', 'Gross Margin' & 'Opeating Leverage' (Trailing 12m Revenue - COGS) / total assets from 12m ago Trailing 12m revenue minus COGS / trailing 12m revenue 12m change in EBIT / 12m change in Sales Average of Z-score of 'Cash Flow Coverage' & 'Cash Flow-to-Debt' (Operating Cash Flows / Total Debt Average of Z-score of 'Capex-to-Sales', 'Y/Y Change in Inventory/Sales' & 'Y/Y Change in Num of Employees' Trailing 12m net capital expenditure / trailing 12m revenue, low values are favored Difference between the most recent Inventory/Sales and Inventory/Sales from 12m ago Y/Y percent change in number of employees Average of Z-score of 'Accruals Sub Composite', 'Earnings Stability Sub Composite', 'Profitability Sub Composite', 'Leverage Sub Composite' & 'Operational Effeciency Sub Composite', 'Earnings Stability Sub Composite', 'Profitability Sub Composite', 'Leverage Sub Composite' & 'Operational Effeciency Sub Composite'					
Quality	Low Accruals Low ST Accruals Earnings Stability Sub Composite Low Estimate Dispersion Low ROE Variability Sales Stability Profitability Sub Composite Gross Profit / Assets Gross Margin Operating Leverage Leverage Sub Composite Cash Flow Coverage Cash Flow Coverage Cash Flow-to-Debt Operational Efficiency Sub Composite Low Capex/Sales YY Change in Inventory/Sales Low Y/Y Change in Num of Employees MS Quality Composite Low Beta	Y/Y change in Net Operating Assets /total assets a year ago, low values are favored Y/Y change in Current Net Operating Assets /Average Assets, low values are favored Average of Z-score of 'Estimate Dispersion', 'ROE Variability' & 'Sales Stability' Sid deviation of IBES EPS estimates divided by absolute value of mean IBES estimate, low values are favored 5-year std deviation of ROE divided by 5-year absolute mean of ROE, low values are favored 5-year std deviation of Y/Y Sales Growth Average of Z-score of ROE, 'Gross Profit-to-Assets', 'Gross Margin' & 'Opeating Leverage' (Trailing 12m Revenue - COGS) / total assets from 12m ago Trailing 12m revenue minus COGS / trailing 12m revenue 12m change in EBIT / 12m change in Sales Average of Z-score of 'Cash Flow Coverage' & 'Cash Flow-to-Debt' (Operating Cash Flows / Total Debt Average of Z-score of 'Capex-to-Sales', 'Y/Y Change in Inventory/Sales' & 'Y/Y Change in Num of Employees' Trailing 12m net capital expenditure / trailing 12m revenue, low values are favored Difference between the most recent Inventory/Sales and Inventory/Sales from 12m ago Y/Y percent change in number of employees Average of Z-score of 'Accruals Sub Composite', 'Earnings Stability Sub Composite', 'Profitability Sub Composite', 'Leverage Sub Composite' & 'Operational Effeciency Sub Composite' 36-month stock beta to the cap-weighted return of stocks, low values are favored					
	Low Accruals Low ST Accruals Earnings Stability Sub Composite Low Estimate Dispersion Low ROE Variability Sales Stability Profitability Sub Composite Gross Profit / Assets Gross Margin Operating Leverage Leverage Sub Composite Cash Flow Coverage Cash Flow Coverage Cash Flow-to-Debt Operational Efficiency Sub Composite Low Capex/Sales Y/Y Change in Inventory/Sales Low Y/Y Change in Num of Employees MS Quality Composite Low Beta Low Volatility	Y/Y change in Net Operating Assets /total assets a year ago, low values are favored Y/Y change in Current Net Operating Assets /Average Assets, low values are favored Average of Z-score of 'Estimate Dispersion', 'ROE Variability' & 'Sales Stability' Sid deviation of IBES EPS estimates divided by absolute value of mean IBES estimate, low values are favored 5-year std deviation of ROE divided by 5-year absolute mean of ROE, low values are favored 5-year std deviation of Y/Y Sales Growth Average of Z-score of ROE, 'Gross Profit-to-Assets', 'Gross Margin' & 'Opeating Leverage' (Trailing 12m Revenue - COGS) / total assets from 12m ago Trailing 12m revenue minus COGS / trailing 12m revenue 12m change in EBIT / 12m change in Sales Average of Z-score of 'Cash Flow Coverage' & 'Cash Flow-to-Debt' (Operating Cash Flows / Total Debt Average of Z-score of 'Capex-to-Sales', 'Y/Y Change in Inventory/Sales' & 'Y/Y Change in Num of Employees' Trailing 12m net capital expenditure / trailing 12m revenue, low values are favored Difference between the most recent Inventory/Sales and Inventory/Sales from 12m ago Y/Y percent change in number of employees Average of Z-score of 'Accruals Sub Composite', 'Earnings Stability Sub Composite', 'Profitability Sub Composite', 'Leverage Sub Composite' & 'Operational Effeciency Sub Composite', 'Earnings Stability Sub Composite', 'Profitability Sub Composite', 'Leverage Sub Composite' & 'Operational Effeciency Sub Composite' Return of stocks, low values are favored Standard deviation of the last 12m returns					

Source: Morgan Stanley Research

Important note regarding economic sanctions. This research references U.S. Executive Order 14032 and/or entities or securities that are designated thereunder. Executive Order 14032 may prohibit U.S. persons from buying certain securities of entities named in this note/presentation. The data set forth in this research is for informational purposes and does not represent Morgan Stanley's view as to whether or not any of the instruments discussed in this note are subject to sanctions. Any references in this report to entities, debt or equity instruments that may be covered by such sanctions should not be read as recommending or advising as to any investment activities in relation to such entities or instruments. Users of this report are solely responsible for ensuring that their investment activities in relation to any sanctioned entities and/or securities are carried out in compliance with applicable sanctions.



Disclosure Section

The information and opinions in Morgan Stanley Research were prepared or are disseminated by Morgan Stanley Asia Limited (which accepts the responsibility for its contents) and/or Morgan Stanley Asia (Singapore) Pte. (Registration number 199206298Z) and/or Morgan Stanley Asia (Singapore) Securities Pte Ltd (Registration number 200008434H), regulated by the Monetary Authority of Singapore (which accepts legal responsibility for its contents and should be contacted with respect to any matters arising from, or in connection with, Morgan Stanley Research), and/or Morgan Stanley Taiwan Limited and/or Morgan Stanley & Co International plc, Seoul Branch, and/or Morgan Stanley Australia Limited (A.B.N. 67 003 734 576, holder of Australian financial services license No. 233742, which accepts responsibility for its contents), and/or Morgan Stanley Wealth Management Australia Pty Ltd (A.B.N. 19 009 145 555, holder of Australian financial services license No. 240813, which accepts responsibility for its contents), and/or Morgan Stanley India Company Private Limited having Corporate Identification No (CIN) U22990MH1998PTC115305, regulated by the Securities and Exchange Board of India ("SEBI") and holder of licenses as a Research Analyst (SEBI Registration No. INH000001105); Stock Broker (SEBI Stock Broker Registration No. INZ000244438), Merchant Banker (SEBI Registration No. INM000011203), and depository participant with National Securities Depository Limited (SEBI Registration No. IN-DP-NSDL-567-2021) having registered office at 18th Floor, Tower 2, One World Center, Plot- 841, Jupiter Textile Mill Compound, Senapati Bapat Marg, Lower Parel, Mumbai 400013, India Telephone no. +91-22-61181000; Compliance Officer Details: Mr. Tejarshi Hardas, Tel. No.: +91-22-61181000 or Email: tejarshi.hardas@morganstanley.com; Grievance officer details: Mr. Tejarshi Hardas, Tel. No.: +91-22-61181000 or Email: msic-compliance@morganstanley.com which accepts the responsibility for its contents and should be contacted with respect to any matt

For important disclosures, stock price charts and equity rating histories regarding companies that are the subject of this report, please see the Morgan Stanley Research Disclosure Website at www.morganstanley.com/researchdisclosures, or contact your investment representative or Morgan Stanley Research at 1585 Broadway, (Attention: Research Management), New York, NY, 10036 LISA

For valuation methodology and risks associated with any recommendation, rating or price target referenced in this research report, please contact the Client Support Team as follows: US/Canada +1 800 303-2495; Hong Kong +852 2848-5999; Latin America +1 718 754-5444 (U.S.); London +44 (0)20-7425-8169; Singapore +65 6834-6860; Sydney +61 (0)2-9770-1505; Tokyo +81 (0)3-6836-9000. Alternatively you may contact your investment representative or Morgan Stanley Research at 1585 Broadway, (Attention: Research Management), New York, NY 10036 USA.

Analyst Certification

The following analysts hereby certify that their views about the companies and their securities discussed in this report are accurately expressed and that they have not received and will not receive direct or indirect compensation in exchange for expressing specific recommendations or views in this report: Daniel K Blake; Jonathan F Garner; Crystal Ng; Jason Ng, CFA; Gilbert Wong, CFA.

Global Research Conflict Management Policy

Morgan Stanley Research has been published in accordance with our conflict management policy, which is available at www.morganstanley.com/institutional/research/conflictpolicies. A Portuguese version of the policy can be found at www.morganstanley.com.br

Important Regulatory Disclosures on Subject Companies

The equity research analysts or strategists principally responsible for the preparation of Morgan Stanley Research have received compensation based upon various factors, including quality of research, investor client feedback, stock picking, competitive factors, firm revenues and overall investment banking revenues. Equity Research analysts' or strategists' compensation is not linked to investment banking or capital markets transactions performed by Morgan Stanley or the profitability or revenues of particular trading desks.

Morgan Stanley and its affiliates do business that relates to companies/instruments covered in Morgan Stanley Research, including market making, providing liquidity, fund management, commercial banking, extension of credit, investment services and investment banking. Morgan Stanley sells to and buys from customers the securities/instruments of companies covered in Morgan Stanley Research on a principal basis. Morgan Stanley may have a position in the debt of the Company or instruments discussed in this report. Morgan Stanley trades or may trade as principal in the debt securities (or in related derivatives) that are the subject of the debt research report.

Certain disclosures listed above are also for compliance with applicable regulations in non-US jurisdictions.

STOCK RATINGS

Morgan Stanley uses a relative rating system using terms such as Overweight, Equal-weight, Not-Rated or Underweight (see definitions below). Morgan Stanley does not assign ratings of Buy, Hold or Sell to the stocks we cover. Overweight, Equal-weight, Not-Rated and Underweight are not the equivalent of buy, hold and sell. Investors should carefully read the definitions of all ratings used in Morgan Stanley Research. In addition, since Morgan Stanley Research contains more complete information concerning the analyst's views, investors should carefully read Morgan Stanley Research, in its entirety, and not infer the contents from the rating alone. In any case, ratings (or research) should not be used or relied upon as investment advice. An investor's decision to buy or sell a stock should depend on individual circumstances (such as the investor's existing holdings) and other considerations.

Global Stock Ratings Distribution

(as of February 29, 2024)

The Stock Ratings described below apply to Morgan Stanley's Fundamental Equity Research and do not apply to Debt Research produced by the Firm.

For disclosure purposes only (in accordance with FINRA requirements), we include the category headings of Buy, Hold, and Sell alongside our ratings of Overweight, Equal-weight, Not-Rated and Underweight. Morgan Stanley does not assign ratings of Buy, Hold or Sell to the stocks we cover. Overweight, Equal-weight, Not-Rated and Underweight are not the equivalent of buy, hold, and sell but represent recommended relative weightings (see definitions below). To satisfy regulatory requirements, we correspond Overweight, our most positive stock rating, with a buy recommendation; we correspond Equal-weight and Not-Rated to hold and Underweight to sell recommendations, respectively.



	Coverage Universe			stment Banking Clients	Other Material Investment Services Clients (MISC)		
Stock Rating Category	Count	% of Total	Count	% of Total IBC	% of Rating Category	Count	% of Total Other MISC
Overweight/Buy	1425	38%	296	43%	21%	626	40%
Equal-weight/Hold	1704	45%	321	46%	19%	718	45%
Not-Rated/Hold	3	0%	0	0%	0%	1	0%
Underweight/Sell	634	17%	76	11%	12%	239	15%
Total	3,766		693			1584	

Data include common stock and ADRs currently assigned ratings. Investment Banking Clients are companies from whom Morgan Stanley received investment banking compensation in the last 12 months. Due to rounding off of decimals, the percentages provided in the "% of total" column may not add up to exactly 100 percent.

Analyst Stock Ratings

Overweight (O). The stock's total return is expected to exceed the average total return of the analyst's industry (or industry team's) coverage universe, on a risk-adjusted basis, over the next 12-18 months.

Equal-weight (E). The stock's total return is expected to be in line with the average total return of the analyst's industry (or industry team's) coverage universe, on a risk-adjusted basis, over the next 12-18 months.

Not-Rated (NR). Currently the analyst does not have adequate conviction about the stock's total return relative to the average total return of the analyst's industry (or industry team's) coverage universe, on a risk-adjusted basis, over the next 12-18 months.

Underweight (U). The stock's total return is expected to be below the average total return of the analyst's industry (or industry team's) coverage universe, on a risk-adjusted basis, over the next 12-18 months.

Unless otherwise specified, the time frame for price targets included in Morgan Stanley Research is 12 to 18 months.

Analyst Industry Views

Attractive (A): The analyst expects the performance of his or her industry coverage universe over the next 12-18 months to be attractive vs. the relevant broad market benchmark, as indicated below.

In-Line (1): The analyst expects the performance of his or her industry coverage universe over the next 12-18 months to be in line with the relevant broad market benchmark, as indicated below. Cautious (C): The analyst views the performance of his or her industry coverage universe over the next 12-18 months with caution vs. the relevant broad market benchmark, as indicated below. Benchmarks for each region are as follows: North America - S&P 500; Latin America - relevant MSCI country index or MSCI Latin America Index; Europe - MSCI Europe; Japan - TOPIX; Asia - relevant MSCI country index or MSCI sub-regional index or MSCI AC Asia Pacific ex Japan Index.

Important Disclosures for Morgan Stanley Smith Barney LLC & E*TRADE Securities LLC Customers

Important disclosures regarding the relationship between the companies that are the subject of Morgan Stanley Research and Morgan Stanley Smith Barney LLC or Morgan Stanley or any of their affiliates, are available on the Morgan Stanley Wealth Management disclosure website at www.morganstanley.com/online/researchdisclosures. For Morgan Stanley specific disclosures, you may refer to www.morganstanley.com/researchdisclosures.

Each Morgan Stanley research report is reviewed and approved on behalf of Morgan Stanley Smith Barney LLC and E*TRADE Securities LLC. This review and approval is conducted by the same person who reviews the research report on behalf of Morgan Stanley. This could create a conflict of interest.

Other Important Disclosures

Morgan Stanley Research policy is to update research reports as and when the Research Analyst and Research Management deem appropriate, based on developments with the issuer, the sector, or the market that may have a material impact on the research views or opinions stated therein. In addition, certain Research publications are intended to be updated on a regular periodic basis (weekly/monthly/quarterly/annual) and will ordinarily be updated with that frequency, unless the Research Analyst and Research Management determine that a different publication schedule is appropriate based on current conditions.

Morgan Stanley is not acting as a municipal advisor and the opinions or views contained herein are not intended to be, and do not constitute, advice within the meaning of Section 975 of the Dodd-Frank Wall Street Reform and Consumer Protection Act.

Morgan Stanley produces an equity research product called a "Tactical Idea." Views contained in a "Tactical Idea" on a particular stock may be contrary to the recommendations or views expressed in research on the same stock. This may be the result of differing time horizons, methodologies, market events, or other factors. For all research available on a particular stock, please contact your sales representative or go to Matrix at http://www.morganstanley.com/matrix.

Morgan Stanley Research is provided to our clients through our proprietary research portal on Matrix and also distributed electronically by Morgan Stanley to clients. Certain, but not all, Morgan Stanley Research products are also made available to clients through third-party vendors or redistributed to clients through alternate electronic means as a convenience. For access to all available Morgan Stanley Research, please contact your sales representative or go to Matrix at http://www.morganstanley.com/matrix.

Any access and/or use of Morgan Stanley Research is subject to Morgan Stanley's Terms of Use (http://www.morganstanley.com/terms.html). By accessing and/or using Morgan Stanley Research, you are indicating that you have read and agree to be bound by our Terms of Use (http://www.morganstanley.com/terms.html). In addition you consent to Morgan Stanley processing your personal data and using cookies in accordance with our Privacy Policy and our Global Cookies Policy (http://www.morganstanley.com/privacy_pledge.html), including for the purposes of setting your preferences and to collect readership data so that we can deliver better and more personalized service and products to you. To find out more information about how Morgan Stanley processes personal data, how we use cookies and how to reject cookies see our Privacy Policy and our Global Cookies Policy (http://www.morganstanley.com/privacy_pledge.html).

If you do not agree to our Terms of Use and/or if you do not wish to provide your consent to Morgan Stanley processing your personal data or using cookies please do not access our research. Morgan Stanley Research does not provide individually tailored investment advice. Morgan Stanley Research has been prepared without regard to the circumstances and objectives of those who receive it. Morgan Stanley recommends that investors independently evaluate particular investments and strategies, and encourages investors to seek the advice of a financial adviser. The appropriateness of an investment or strategy will depend on an investor's circumstances and objectives. The securities, instruments, or strategies discussed in Morgan Stanley Research



may not be suitable for all investors, and certain investors may not be eligible to purchase or participate in some or all of them. Morgan Stanley Research is not an offer to buy or sell or the solicitation of an offer to buy or sell any security/instrument or to participate in any particular trading strategy. The value of and income from your investments may vary because of changes in interest rates, foreign exchange rates, default rates, prepayment rates, securities/instruments prices, market indexes, operational or financial conditions of companies or other factors. There may be time limitations on the exercise of options or other rights in securities/instruments transactions. Past performance is not necessarily a guide to future performance. Estimates of future performance are based on assumptions that may not be realized. If provided, and unless otherwise stated, the closing price on the cover page is that of the primary exchange for the subject company's securities/instruments.

The fixed income research analysts, strategists or economists principally responsible for the preparation of Morgan Stanley Research have received compensation based upon various factors, including quality, accuracy and value of research, firm profitability or revenues (which include fixed income trading and capital markets profitability or revenues), client feedback and competitive factors. Fixed Income Research analysts', strategists' or economists' compensation is not linked to investment banking or capital markets transactions performed by Morgan Stanley or the profitability or revenues of particular trading desks.

The "Important Regulatory Disclosures on Subject Companies" section in Morgan Stanley Research lists all companies mentioned where Morgan Stanley owns 1% or more of a class of common equity securities of the companies. For all other companies mentioned in Morgan Stanley Research, Morgan Stanley may have an investment of less than 1% in securities/instruments or derivatives of securities/instruments of companies and may trade them in ways different from those discussed in Morgan Stanley Research. Employees of Morgan Stanley not involved in the preparation of Morgan Stanley Research may have investments in securities/instruments or derivatives of securities/instruments of companies mentioned and may trade them in ways different from those discussed in Morgan Stanley Research. Derivatives may be issued by Morgan Stanley or associated persons.

With the exception of information regarding Morgan Stanley, Morgan Stanley Research is based on public information. Morgan Stanley makes every effort to use reliable, comprehensive information, but we make no representation that it is accurate or complete. We have no obligation to tell you when opinions or information in Morgan Stanley Research change apart from when we intend to discontinue equity research coverage of a subject company. Facts and views presented in Morgan Stanley Research have not been reviewed by, and may not reflect information known to, professionals in other Morgan Stanley business areas, including investment banking personnel.

Morgan Stanley Research personnel may participate in company events such as site visits and are generally prohibited from accepting payment by the company of associated expenses unless pre-approved by authorized members of Research management.

Morgan Stanley may make investment decisions that are inconsistent with the recommendations or views in this report.

To our readers based in Taiwan or trading in Taiwan securities/instruments: Information on securities/instruments that trade in Taiwan is distributed by Morgan Stanley Taiwan Limited (*MSTL*). Such information is for your reference only. The reader should independently evaluate the investment risks and is solely responsible for their investment decisions. Morgan Stanley Research may not be distributed to the public media or quoted or used by the public media without the express written consent of Morgan Stanley. Any non-customer reader within the scope of Article 7-1 of the Taiwan Stock Exchange Recommendation Regulations accessing and/or receiving Morgan Stanley Research is not permitted to provide Morgan Stanley Research to any third party (including but not limited to related parties, affiliated companies and any other third parties) or engage in any activities regarding Morgan Stanley Research which may create or give the appearance of creating a conflict of interest. Information on securities/instruments that do not trade in Taiwan is for informational purposes only and is not to be construed as a recommendation or a solicitation to trade in such securities/instruments. MSTL may not execute transactions for clients in these securities/instruments.

Certain information in Morgan Stanley Research was sourced by employees of the Shanghai Representative Office of Morgan Stanley Asia Limited for the use of Morgan Stanley Asia Limited. Morgan Stanley is not incorporated under PRC law and the research in relation to this report is conducted outside the PRC. Morgan Stanley Research does not constitute an offer to sell or the solicitation of an offer to buy any securities in the PRC. PRC investors shall have the relevant qualifications to invest in such securities and shall be responsible for obtaining all relevant approvals, licenses, verifications and/or registrations from the relevant governmental authorities themselves. Neither this report nor any part of it is intended as, or shall constitute, provision of any consultancy or advisory service of securities investment as defined under PRC law. Such information is provided for your reference only.

Morgan Stanley Research is disseminated in Brazil by Morgan Stanley C.T.V.M. S.A. located at Av. Brigadeiro Faria Lima, 3600, 6th floor, São Paulo - SP, Brazil; and is regulated by the Comissão de Valores Mobiliários; in Mexico by Morgan Stanley México, Casa de Bolsa, S.A. de C.V which is regulated by Comision Nacional Bancaria y de Valores. Paseo de los Tamarindos 90, Torre 1, Col. Bosques de las Lomas Floor 29, 05120 Mexico City; in Japan by Morgan Stanley MUFG Securities Co., Ltd. and, for Commodities related research reports only, Morgan Stanley Capital Group Japan Co., Ltd; in Hong Kong by Morgan Stanley Asia Limited (which accepts responsibility for its contents) and by Morgan Stanley Bank Asia Limited; in Singapore by Morgan Stanley Asia (Singapore) Pte. (Registration number 199206298Z) and/or Morgan Stanley Asia (Singapore) Securities Pte Ltd (Registration number 200008434H), regulated by the Monetary Authority of Singapore (which accepts legal responsibility for its contents and should be contacted with respect to any matters arising from, or in connection with, Morgan Stanley Research) and by Morgan Stanley Bank Asia Limited, Singapore Branch (Registration number T14FC0118)); in Australia to "wholesale clients" within the meaning of the Australian Corporations Act by Morgan Stanley Australia Limited A.B.N. 67 003 734 576, holder of Australian financial services license No. 233742, which accepts responsibility for its contents; in Australia to "wholesale clients" and "retail clients" within the meaning of the Australian Corporations Act by Morgan Stanley Wealth Management Australia Pty Ltd (A.B.N. 19 009 145 555, holder of Australian financial services license No. 240813, which accepts responsibility for its contents; in Korea by Morgan Stanley & Co International plc, Seoul Branch; in India by Morgan Stanley India Company Private Limited having Corporate Identification No (CIN) U22990MH1998PTC115305, regulated by the Securities and Exchange Board of India ("SEBI") and holder of licenses as a Research Analyst (SEBI Registration No. INH000001105); Stock Broker (SEBI Stock Broker Registration No. INZ000244438), Merchant Banker (SEBI Registration No. INM000011203), and depository participant with National Securities Depository Limited (SEBI Registration No. IN-DP-NSDL-567-2021) having registered office at 18th Floor, Tower 2, One World Center, Plot-841, Jupiter Textile Mill Compound, Senapati Bapat Marg, Lower Parel, Mumbai 400013, India Telephone no. +91-22-61181000; Compliance Officer Details: Mr. Tejarshi Hardas, Tel. No.: +91-22-61181000 or Email: tejarshi.hardas@morganstanley.com; Grievance officer details: Mr. Tejarshi Hardas, Tel. No.: +91-22-61181000 or Email: msic-compliance@morganstanley.com; in Canada by Morgan Stanley Canada Limited; in Germany and the European Economic Area where required by Morgan Stanley Europe S.E., authorised and regulated by Bundesanstalt fuer Finanzdienstleistungsaufsicht (BaFin) under the reference number 149169; in the US by Morgan Stanley & Co. LLC, which accepts responsibility for its contents. Morgan Stanley & Co. International plc, authorized by the Prudential Regulation Authority and regulated by the Financial Conduct Authority and the Prudential Regulation Authority, disseminates in the UK research that it has prepared, and research which has been prepared by any of its affiliates, only to persons who (i) are investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended, the "Order"); (ii) are persons who are high net worth entities falling within Article 49(2)(a) to (d) of the Order; or (iii) are persons to whom an invitation or inducement to engage in investment activity (within the meaning of section 21 of the Financial Services and Markets Act 2000, as amended) may otherwise lawfully be communicated or caused to be communicated. RMB Morgan Stanley Proprietary Limited is a member of the JSE Limited and A2X (Pty) Ltd. RMB Morgan Stanley Proprietary Limited is a joint venture owned equally by Morgan Stanley International Holdings and A2X (Pty) and AInc. and RMB Investment Advisory (Proprietary) Limited, which is wholly owned by FirstRand Limited. The information in Morgan Stanley Research is being disseminated by Morgan Stanley Saudi Arabia, regulated by the Capital Market Authority in the Kingdom of Saudi Arabia, and is directed at Sophisticated investors only.

The information in Morgan Stanley Research is being communicated by Morgan Stanley & Co. International plc (DIFC Branch), regulated by the Dubai Financial Services Authority (the DFSA), and is directed at Professional Clients only, as defined by the DFSA. The financial products or financial services to which this research relates will only be made available to a customer who we are satisfied meets the regulatory criteria to be a Professional Client. A distribution of the different MS Research ratings or recommendations, in percentage terms for Investments in each



sector covered, is available upon request from your sales representative.

The information in Morgan Stanley Research is being communicated by Morgan Stanley & Co. International plc (QFC Branch), regulated by the Qatar Financial Centre Regulatory Authority (the QFCRA), and is directed at business customers and market counterparties only and is not intended for Retail Customers as defined by the QFCRA.

As required by the Capital Markets Board of Turkey, investment information, comments and recommendations stated here, are not within the scope of investment advisory activity. Investment advisory service is provided exclusively to persons based on their risk and income preferences by the authorized firms. Comments and recommendations stated here are general in nature. These opinions may not fit to your financial status, risk and return preferences. For this reason, to make an investment decision by relying solely to this information stated here may not bring about outcomes that fit your expectations.

The trademarks and service marks contained in Morgan Stanley Research are the property of their respective owners. Third-party data providers make no warranties or representations relating to the accuracy, completeness, or timeliness of the data they provide and shall not have liability for any damages relating to such data. The Global Industry Classification Standard (GICS) was developed by and is the exclusive property of MSCI and S&P.

Morgan Stanley Research, or any portion thereof may not be reprinted, sold or redistributed without the written consent of Morgan Stanley.

Indicators and trackers referenced in Morgan Stanley Research may not be used as, or treated as, a benchmark under Regulation EU 2016/1011, or any other similar framework.

The issuers and/or fixed income products recommended or discussed in certain fixed income research reports may not be continuously followed. Accordingly, investors should regard those fixed income research reports as providing stand-alone analysis and should not expect continuing analysis or additional reports relating to such issuers and/or individual fixed income products. Morgan Stanley may hold, from time to time, material financial and commercial interests regarding the company subject to the Research report.

Registration granted by SEBI and certification from the National Institute of Securities Markets (NISM) in no way guarantee performance of the intermediary or provide any assurance of returns to investors. Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

© 2024 Morgan Stanley